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Abstract 
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL 
ECVAM) Strategy Document on Toxicokinetics (TK) outlines strategies to enable 
prediction of systemic toxicity by applying new approach methodologies (NAM). The 
central feature of the strategy focuses on using physiologically-based kinetic (PBK) 
modelling to integrate data generated by in vitro and in silico methods for absorption, 
distribution, metabolism, and excretion (ADME) in humans for predicting whole-body TK 
behaviour, for environmental chemicals, drugs, nano-materials, and mixtures. In order 
to facilitate acceptance and use of this new generation of PBK models, which do not rely 
on animal/human in vivo data in the regulatory domain, experts were invited by EURL 
ECVAM to (i) identify current challenges in the application of PBK modelling to support 
regulatory decision making; (ii) discuss challenges in constructing models with no in vivo 
kinetic data and opportunities for estimating parameter values using in vitro and in silico 
methods; (iii) present the challenges in assessing model credibility relying on non-animal 
data and address strengths, uncertainties and limitations in such an approach; (iv) 
establish a good kinetic modelling practice workflow to serve as the foundation for 
guidance on the generation and use of in vitro and in silico data to construct PBK models 
designed to support regulatory decision making.  
To gauge the current state of PBK applications, experts were asked upfront of the 
workshop to fill a short survey. In the workshop, using presentations and discussions, 
the experts elaborated on the importance of being transparent about the model 
construct, assumptions, and applications to support assessment of model credibility. The 
experts offered several recommendations to address commonly perceived limitations of 
parameterization and evaluation of PBK models developed using non-animal data and its 
use in risk assessment, these include: (i) develop a decision tree for model construction; 
(ii) set up a task force for independent model peer review; (iii) establish a scoring 
system for model evaluation; (iv) attract additional funding to develop accessible 
modelling software.; (v) improve and facilitate communication between scientists (model 
developers, data provider) and risk assessors/regulators; and (vi) organise specific 
training for end users. The experts also acknowledged the critical need for developing a 
guidance document on building, characterising, reporting and documenting PBK models 
using non-animal data. This document would also need to include guidance on 
interpreting the model analysis for various risk assessment purposes, such as 
incorporating PBK models in integrated strategy approaches and integrating them with in 
vitro toxicity testing and adverse outcome pathways. This proposed guidance document 
will promote the development of PBK models using in vitro and silico data and facilitate 
the regulatory acceptance of PBK models for assessing safety of chemicals. 
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1 Introduction  
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL 
ECVAM) Strategy Document on Toxicokinetics (TK)1 outlines the strategies to enable 
prediction of systemic toxicity by applying new approach methodologies (NAM) that 
include toxicokinetic (TK) considerations. The central feature of the strategy focuses on 
using physiologically-based kinetic (PBK)2 modelling to integrate data generated by in 
vitro and in silico methods for absorption, distribution, metabolism and excretion (ADME) 
in humans for predicting whole-body TK behaviour. In PBK models, the body is 
represented as interconnected compartments linked via blood flow. PBK models use 
differential equations to describe the ADME processes that govern the fate of the 
chemical within the body. These models are able to simulate concentration-time curves, 
in target organs and in blood. The proper use of PBK models can reduce uncertainties 
and identify gaps that currently exist in risk assessments that use default extrapolation 
factors (e.g., 10x for inter-species extrapolation) to estimate human health risks based 
on in vivo animal toxicity studies. PBK models provide the scientific basis on physiology 
and TK for extrapolations across species, life-stages, routes of exposure, and exposure 
scenarios. PBK models also provide the means for estimating health risks on both the 
individual and population levels. In the past, quantitative knowledge of the in vivo 
tissue/blood concentration-time relationship was a prerequisite for calibrating and 
evaluating the predictive capability of a PBK model. Today, new generations of PBK 
models are increasingly being developed, using non-animal data, as the field of risk 
assessment evolves towards the goal of reducing, and eventually replacing, the use of 
animals for predicting toxicity in humans. 
In order to facilitate acceptance and use of this new generation of PBK models in the 
regulatory domain, experts were invited by the EURL ECVAM to attend a two-day 
workshop entitled “PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK 
ASSESSMENT – REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING” 
on the 16th -17th of November 2016 at the Joint Research Centre (JRC) in Ispra, Italy. 
The main objectives of this workshop were to (i) identify current challenges in the 
application of PBK modelling to support regulatory decision making; (ii) discuss 
challenges in constructing models with no in vivo kinetic and dynamic data and 
opportunities for estimating parameter values using in vitro and in silico methods; (iii) 
present the challenges in assessing credibility of models relying on non-animal data and 
address strengths, uncertainties and limitations; (iv) establish a good kinetic modelling 
practice workflow to serve as the foundation for guidance on the generation and use of 
in vitro and in silico data to construct PBK models designed to support regulatory 
decision making. 
1.1 Historical Background 
The 2016 JRC workshop was organized with the aim of highlighting the construction, 
validation, and promotion of PBK models that rely only on non-animal measurements 
and predictions. This workshop did not reiterate the issues that have been tackled in 
previous PBK modelling-related workshops. The prior workshops (Table 1), as well as the 
available guidance documents, dedicated to PBK modelling in the last two decades are 
briefly summarized below.  
 
The US Environmental Protection Agency (EPA), in 2006, published the document 
entitled "Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) 
Models and Supporting Data in Risk Assessment"3, which serves as a learning tool for 
scientists and risk assessors, and addresses the application and evaluation of PBK 
models for risk assessment purposes. In addition, this document can be informative to 
                                           
1http://publications.jrc.ec.europa.eu/repository/bitstream/JRC96418/eurl%20ecvam%20toxicokinetics%20stra
tegy.pdf  
2 PBK: is synonyms of PBPK, PBBK, PBTK and is used in this report to define physiologically based kinetic 
models.  
3 https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=157668&CFID=68657522&CFTOKEN=85518773. 
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PBK model developers because it provides an overview of the types of data and models 
that EPA requires for consideration of a model for use in risk assessment. The EPA 
document aimed to address the following three questions: Why are risk assessors 
interested in using PBK models? How are PBK models evaluated for use in a risk 
assessment? What are the questions or data gaps in a risk assessment that can be 
addressed by PBK models?  
 
The World Health Organization (WHO), in 2010, published a guidance document on 
"Principles of Characterizing and Applying PBK Models in Risk Assessment"4 to promote 
best practice in PBK modelling, including transparency, to facilitate understanding and 
sharing of these models in risk assessment reports. In addition, Meek et al., (2013) 
reported several case studies illustrating the approach established by the WHO 
International Programme of Chemical Safety (IPCS) on characterization and application 
of PBK models in risk assessment.  
 
The European Food Safety Authority published, in 2014, a scientific opinion on good 
modelling practice in the context of mechanistic effect models for risk assessment of 
plant protection products5. The opinion identified several critical steps for using 
environmental models in risk assessment, such as problem formulation, model domain of 
applicability, selection of environmental scenario for pesticides, toxicokinetic 
characteristics, and species selection. 
 
The European Committee for Standardization (CEN) (2015) organized a workshop on 
“Standard documentation of large chemical exposure models” in 2015. The resulting CEN 
workshop agreement (CWA) was expected to facilitate a more rigorous formulation of 
exposure models description and the understanding by users. The main outcome was a 
CEN CWA document which establishes terms and definitions for exposure models and 
their elements, specifies minimum requirements for the amount and type of information 
to be documented, and proposes a structure for communicating the documentation to 
different users (Ciffroy et al., 2016). 
 
In the pharmaceutical field, the European Medicines Agency (EMA) has an on-going 
effort to harmonize the utilization of PBK model platforms in drug submission to the 
EMA. The EMA published, in July 2016, a “Guideline on the qualification and reporting of 
PBK modelling and simulation”. The US Food and Drug Administration (FDA) also 
published, in December 2016, guidance on “PBK Analyses-Format and Content - 
Guidance for industry”. Both documents are currently undergoing a public comment 
period. In addition to these agency documents, Certara has recently summarized recent 
advances in development and application of PBK models to support regulatory decision 
making in the pharmaceutical field (Jamei, 2016; Zhuang et al., 2016). 
 
The 2016 JRC workshop had a different theme from these previous workshops and 
guidance documents, even though several fundamental requirements for PBK modelling 
identified in those previous efforts are still valid. In the 2016 JRC workshop, 
requirements for developing, documenting and evaluating in PBK models without the use 
of in vivo pharmacokinetic data were discussed. The outcome of this workshop was a 
workflow that can support the future development of a Good Kinetic Modelling Practices 
on the generation and use of in vitro and in silico data to construct PBK models for 
supporting regulatory decision-making. Figure 1 describes the steps of a workflow 
already established in the EPA guidance, as well as in the WHO/IPCS. The workshop 
outputs will be added to extend this existing workflow. The extended workflow should 
not only help in the PBK model development/documentation of this new generation of 
PBK models built with only alternative data, but also aid risk assessors in better 
understanding/interpreting the PBK model analysis.   
                                           
4 http://www.who.int/ipcs/methods/harmonization/areas/pbpk/en/ 
5 https://www.efsa.europa.eu/it/efsajournal/pub/3589 
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Table 1. Twenty years of PBK models workshops 1995-2016. Abbreviations- European Partnership for Alternative Approaches to Animal Testing (EPAA); 
National Institute of Environmental Health Sciences (NIEHS); Institut national de l'environnement industriel et des risques (INERIS); Good Modelling 
Practice (GMP). 
 
Workshop Title Date, Location Workshop 
Host/organizer 
Notes conclusions 
Application of Physiologically-based 
Pharmacokinetic (PBPK) Modelling to 
Support Dose Selection. 10 March 
2014. White Oak Campus, Silver 
Spring, MD, USA 
US FDA 
 
 
 
 
The workshop endeavoured to (i) assess the current state of knowledge in 
the application of PBK in regulatory decision-making, and (ii) share and 
discuss best practices in the use of PBK modelling to inform dose selection 
in specific patient populations (Wagner et al., 2015). 
 
‘‘Potential for further integration of 
toxicokinetic modelling into the 
prediction of in vivo dose–response 
curves without animal experiments’’. 
13-14 October, 2011. Joint Research 
Centre, Italy  
 
 
 
 
 
EPAA & EURL ECVAM 
 
 
 
 
 
 
 
 
 
 
The aim of the workshop was to critically appraise PBK modelling software 
platforms as well as a more detailed state-of-the-art overview of non-
animal based PBK parameterisation tools. Such as: 1) Identification of 
gaps in non-animal test methodology for the assessment of ADME. 
2) Addressing user-friendly PBK software tools and free-to-use web 
applications. 3) Understanding the requirements for wider and increased 
take up and use of PBK modelling by regulators, risk assessors and 
toxicologists in general. 4) Tackling the aspect of obtaining in vivo human 
toxicokinetic reference data via micro-dosing following the increased 
interest by the research community, regulators and politicians (Bessems et 
al., 2014). 
The International Workshop on the 
Development of GMP for PBPK 
models.  
26-28 April 2007, Crete, Greece 
 
 
 
 
  
The Mediterranean 
Agronomic Institute 
of Chaina 
 
 
 
 
 
 
Clear descriptions of good practices for (1) model development i.e., 
research and analysis activities, (2) model characterization i.e., methods 
to describe how consistent the model is with biology and the strengths and 
limitations of available models and data, such as sensitivity analyses, (3) 
model documentation, and (4) model evaluation i.e., independent review 
that will assist risk assessors in their decisions of whether and how to use 
the models, and also for model developers to understand expectations of 
various model purposes e.g., research versus application in risk 
assessment (Loizou et al in 2008). 
Uncertainty and Variability in PBPK 
Models. 31st October - 2nd November 
2006, RTP, NC, USA  
 
 
EPA/NIEHS/CIIT/ 
INERIS 
 
 
 
Better Statistical Models and Methods; Better Databases for physiological 
properties and their variation; Explore a wide range of Chemical Space; 
Training, Documentation and Software. 
The outcome of this workshop has been summarized by 
Barton et al. (2007). 
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Physiologically Based Kinetic (PBK) 
modelling: Meeting the 3Rs 
Agendas, October 10-12, 2005, 
Ispra, Italy 
 
 
 
 
 
 
ECVAM 
 
 
 
 
 
 
 
 
 
To better define the potential role of PBK modelling as a set of techniques 
capable of contributing to the reduction, refinement and replacement of 
the use of laboratory animals in the risk assessment process of potentially 
toxic chemicals; discuss the need for technical improvements and 
applications; to identify the need to increase understanding and 
acceptance by regulatory authorities of the capabilities and limitations of 
these models in toxicological risk assessment. The recommendations were 
categorised into i) quality of PBK modelling; ii) availability of reference 
data and models; and iii) development of testing strategy (Bouvier 
d’Yvoire et al., 2007). 
The use of biokinetics and in vitro 
methods in toxicological risk 
evaluation, 1995, Utrecht, The 
Netherlands  
 
 
 
 
 
 
 
 
 
ECVAM 
 
 
 
 
 
 
 
 
 
 
 
 
Reports fifteen (15) recommendations to encourage and guide future work 
in the PBK model field. 1. Explore possibilities to integrate in vitro data into 
the models; 2. Models are built on a case by case basis; 3. Establish 
documentation to illustrate what is needed experimentally; 4. Availability 
of data required for constructing models; 5. Establish databases; 6. Refine 
the partition coefficient; 7. Penetration rate should be incorporated into 
PBK models (barriers information); 8. Biotransformation CYP P450 
reactions and information should be included into the model; 9. Emphasis 
on species comparison (rodent vs human); 10. Target organs and 
metabolism; 11. In vitro systems should be a reliable representation of in 
vivo; 12. PBK models should include dynamics; 13.Validation of PBK 
models should be done with independent data set; 14. Evaluation of the 
different software are; 15. Sensitivity analysis employed to identify 
potential source of errors (Blaauboer et al., 1996). 
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Figure 1. Proposed workflow as basis for writing the guidance document (adapted from Rietjens 
et al., 2011).   
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1.2 Internal Survey 
The experts that were invited to the EURL ECVAM PBK Model Workshop were asked 
beforehand to fill in a brief questionnaire on PBK modelling. This survey was conducted 
to get a general perspective of the participant’s views on the topic (chapter 2).  
1.3 In vitro to in vivo extrapolation  
In vitro (within the glass) refers to the technique of performing a given procedure in a 
controlled environment outside of a living organism.  In vivo (with in the living) refers in 
toxicology research to experimentation using a whole. Living organism as opposed to a 
partial or dead organism. Several works and workshop reports on the in vitro to in vivo 
extrapolation (IVIVE) approach are available in the literature; available selected 
reference on this topic are: Blaauboer (2010), Coeke (2013), Wetmore (2013, 2015), 
Groothuis et al., (2015), Yoon, (2014; 2015), Wilk-Zasadna (2015), Chang (2015), and 
most recently Bell et al. (2018). 
Currently, In vitro to in vivo extrapolation refers to two different approaches/models: 
1. To scale up in vitro measured metabolic parameters for use in the PBK model to 
estimate the metabolic clearance in a real in vivo situation (e.g., scaling up intrinsic 
clearance values determined in microsomes to whole liver); 
2. To quantitatively translate a nominal concentration (e.g., a point of departure 
concentration) used in vitro assays to a corresponding exposure dose in vivo (reverse 
dosimetry using PBK models). This process is referred as quantitative in vitro to in vivo 
extrapolation (QIVIVE) and essentially indicates an extrapolation of dose response 
relationships rom in vitro to in vivo. More is discussed in chapter 4.3.2. 
1.4 Workshop Charge Questions 
The workshop was organized into three sessions: (i) Identifying regulatory needs 
(summarized in Chapter 3); (ii) Constructing a PBK model without the use of in vivo data 
(summarized in Chapter 4); and (iii) Assessing model credibility (summarized in Chapter 
5). Each session started with thought-provoking presentations by participating experts. 
Following the presentations, the discussions took place in smaller break-out groups. 
Consensus recommendations among the experts are summarized in Chapter 6.  
 
Charge questions that were discussed during the three sessions are summarized below: 
 Which types of in silico models and high throughput in vitro measurements/data can 
be used to support PBK model development and how can we evaluate them? 
 What are the strengths, uncertainties and limitations in using such in vitro 
measurements and in silico models? 
 How to validate PBK models in the absence of supporting in vivo data? 
 What are the needs and challenges in building an animal free PBK model? 
 How to identify sources of uncertainty in PBK modelling? 
 What are the critical needs for a longer term strategy to incrementally refine and 
deploy PBK modelling in parallel with an appropriate evolution of regulatory 
practice? 
 
Additional documentation on questions for discussion can be found in pre-conference 
material shared between the experts (Annex 1).  
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2 Internal Survey on application of PBK models 
To gather a general perspective of the participant’s views on the application of PBK 
models, an internal survey was performed prior to the workshop. The experts were 
invited to fill in, prior to the JRC workshop, a brief questionnaire on PBK models and 
ADME/TK properties. The questionnaire contained 12 questions of which the first 3 
requested information on the use of PBK models. Questions 4 to 8 were directed more 
on gaining information on computational implementation, model parameterization, and 
model evaluation. Question 9 was an attempt to identify existing gaps in data for model 
parameterization and evaluation. Question 10 referred to extrapolation from in vitro to in 
vivo. Finally, questions 11 and 12 focussed on regulatory acceptance and good modelling 
practices. The results of this survey were presented at the workshop, and they were also 
an integral part of the discussion throughout the workshop.  
Out of the 22 participants invited to the workshop, 14 took the survey. The results are 
summarized below. 
 
 
2.1 Survey Results 
 
Q1. Do you use PBK/PBPK/PBTK models in your current or past daily work?  
 
Figure 2. Pie chart showing participants results in percentage on utilization of PBK. 
 
Out of the 14 participants who took the survey, 21% replied “NO” to this question, the 
remaining 79% replied that they have or are currently applying PBK models in daily 
work. It must be kept in mind that the survey currently was filled out only by experts 
within the field. 
 
 
YES 
36% 
YES for daily work 
22% 
YES, but not 
routinely/not 
curently/not 
often 
21% 
NO 
21% 
14 
 
Q2. For which application(s) do you use PBK modelling (e.g., human or 
ecological health risk assessment, experimental design)?  
 
Figure 3. Pie chart showing participants replies for which application they had used PBK models.  
 
Figure 3 shows PBK models are mainly used for human risk assessment by the workshop 
participants, followed by use for experimental design.  
 
Q3. In which field (e.g., medicine, food safety, REACH)? 
 
Figure 4. Participants responses in percentage on the field in which PBK models are applied.  
 
As it can be seen, experts identified a variety of fields in which PBK models are being 
used. The fields that received more than 10% of responses include pharma, food related, 
personal care product, and Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH). Additionally to the most common fields listed a small percentage 
responded that PBK models are used in analysis and integration of in vitro data and 
processes.  
Human risk assessment
Veterinary
Experimental design
Predict in vivo dose levels
0 2 4 6 8 10 12 14
0% 5% 10% 15% 20% 25%
in vitro
occupational risk assessment
cosmetics
REACH
personal care product
pharma
food related
environmental health/pesticide risk
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Q4. What specific software platform do you use to build PBK models (e.g., 
simCYP, GastroPlus, MATLAB, R, Berkley Madonna)?  
 
 
 
Figure 5. Summary of the most used language/program to write PBK models  
 
The software language R (with MCSim) and Berkely Madonna are the most used 
platforms for PBK modelling among the field experts, followed by ACLSX, MATLAB, 
SimCyp, Gastroplus, ADMET, Rvis, and others. It must be kept in mind that RVis is 
currently under further development. 
 
Q5. Sources of chemical-specific parameters (e.g., partition coefficients, 
metabolism, skin/oral absorption, protein binding) for the model (e.g., in vitro 
system, in silico predictions, database)?  
 
Figure 6. Chart showing the distribution of responses in percentage for the question: where do 
the input parameters come from? (Categories provided: literature, in silico (QSAR prediction), 
direct model estimates, published databases (DB), in vitro data). 
0% 5% 10% 15% 20%
R (with MCSim)
Berkeley Madonna
ACSL/X and ADME products
MATLAB
ACSL/X and ADME products (in the past)
Simcyp
 ADMET Predictor and GastroPlus
other (Merlin-EXPO, IndusChemTOX)
RVIS
0% 5% 10% 15% 20% 25% 30% 35% 40%
in vitro
published DB
in silico (QSAR)
direct estimate/models
literature
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The most used sources for obtaining values for chemical specific parameters are 
literature, in silico such as Quantitative Structure-Activity Relationship (QSAR) 
predictions and published databases (DB). Ad hoc in vitro data is only used by 12 % of 
the participants. 
 
Q6. How do you evaluate model performance? 
This question was an open question, but the answers can be summarized by the 
following types:  
 Model predictions vs experimental data for a set of known compounds; 
 Increased stability by evaluation using range of predicted values; 
 Sensitivity analysis; 
 Independent Expert evaluation. 
 
Q7. What experimental data for ADME are critical to build PBK models? 
The experimental data needed depends of course on the PBK model built, but in general, 
the following set of data was reported to be needed: 
 Metabolism (Vmax, Km) 
 Plasma protein binding 
 Chemical absorption, bioavailability  
 Saturable or linear ADME descriptors 
 Blood:tissue partitioning (Log P/log D) 
 Data on renal excretion 
 Physicochemical properties 
 Intrinsic clearance values 
It was stressed by one respondent that the experimental data needed depends on the 
purpose of the study and the chemical of interest. For some purposes or chemicals, only 
one kinetic parameter may be of importance. Some examples are listed below: 
1) What is a safe daily oral intake for humans of a chemical present in food, knowing 
the dose-response in rats? For modelling such chronic oral exposure, it is usually 
sufficient to have % absorbed, Vmax and Km of disappearance of test substance 
(hepatic clearance) experimentally, for both rats and humans. Partition 
coefficients can be estimated very well (QSARs), however, this is only true for 
certain classes of chemicals. The Poulin et al (2001; 2000) and Schmitt et al 
(2008) family of models work well for most organic molecules, but do not handle 
say metals or perfluorinated compounds. For renal excretion, the glomerular 
filtration rate (GFR) can be used. 
2) What is a safe daily oral intake for humans of a chemical present in foodstuffs, 
knowing the dose-response in rats and seeing the effects found are in the 
foetuses? In this case, the transfer to the placenta may need to be included. 
3) What is a safe daily oral intake for humans of a chemical present in foodstuffs, 
knowing the dose-response in rats and knowing the substance is metabolized by 
an enzyme which has very variable activity in the human population? In this case, 
you might want to include population variability for the metabolism. 
 
Q8. What experimental data for ADME are critical to support extrapolation for 
risk assessment? 
Given the diversity of the answers to this question, the provided answers are 
summarized here in random order: 
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 Ideally, measured data for the dose metric that is being used to assess potential 
adverse and non-adverse effect levels in preclinical tox species and humans. 
Measured data would be required, but these are often not available. 
 If predictions based on the PBK model are e.g. for the blood concentration, in 
vivo data on blood levels (present upon oral dosing) are needed to assess how 
well the model predicts. If specific tissue concentrations are predicted, in vivo 
data on tissue levels would be required, but these are often not available. 
 Time course and dose response data for model calibration and evaluation. Even if 
the goal is to reduce in vivo testing, it would be critical to have these in vivo data 
on some “representative chemicals”. 
 It depends on the details of the model and the kind of extrapolation required. In 
general, anything that differs between the domains (extrapolation from and 
extrapolation to).  
 Data from systemic toxicity studies regarding potential target organs, 
identification of metabolites and their potential fate in the body. 
 Metabolic rate constants and intrinsic clearance values, human exposure data, 
human biological monitoring data and in vitro concentration-response 
relationships. 
 More often it is absorption rates and metabolic elimination that are key. 
Distribution can be estimated as a first tier using QSAR or biological prediction 
models. Urinary excretion can be approached as a first tier using glomerular 
filtration rate in combination with protein binding. But in all cases, any 
assumption should be clearly stated in any discussion/conclusion based on using 
the PBK model at stake. 
 Chemical-specific:  
- Data to verify if fraction of xenobiotic unbound can be extrapolated.  
- Experimental data in the right dose range that is relevant to risk 
assessment.  
- Good specification of ADME that drives target-site concentrations and 
data to extrapolate those driving factors. 
Physiological:  
- Ontogeny information/data on transporters and metabolic enzymes 
(across life-stages and across species)." 
 Data needed for the construction of the PBK model– giving you a conservative 
estimate of risk.  
 Depends on the extrapolation step(s) needed to bridge the extrapolation from the 
hazard Point of Departure (PoD) to the human exposure scenario under 
consideration. If predominantly based on in vitro information, Quantitative IVIVE 
(QIVIVE) will have to be performed which requires a relatively complex model 
with many input parameters. 
 
Q9. What ADME property should be addressed experimentally, that we are 
currently missing for both modelling and risk assessment (e.g. generate more 
data for membranes or bioavailability)? What is your priority? 
The following ADME property as answers were given (in brackets are the numbers of 
respondent selections per property): Metabolism (6), protein binding (3), renal excretion 
(3), transport mediated uptake/efflux (3), absorption skin, gastrointestinal (GI) and 
respiratory tract (2), intrinsic clearance (2), and foetal disposition, placenta barrier (1). 
 
Q10. How do you apply in vitro to in vivo extrapolation? 
 Graphically link the in vivo to in vitro dose using the blood/plasma C,t-curve 
based  
 In vitro ADME measurements (e.g., in vitro metabolism rates, skin absorption 
rates) being scaled up to in vivo ADME rates. 
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 In vitro toxicity assays being linked to in vivo effects using AOPs. For example, 
binding of thyroid peroxidase enzyme with chemicals in vitro may be linked to T4 
inhibition (a key event) and subsequent thyroid function disruption. 
 In vitro dose response data being linked to in vivo blood or target tissue 
concentrations using PBK models. 
Q11. Do you have any challenges or experience to share in gaining regulatory 
acceptance of PBK models? 
Seven participants answered “No”, and seven answered “Yes”, with more specific 
answers were given in the following list:  
 Lack of understanding and expertise 
 Discussion on correct model type to use, model complexity 
 Lack of libraries containing parameters to use within user friendly models 
 Need for higher level of confidence 
Q12. Define "GOOD MODELING PRACTICE" (in 3 sentences)  
The following answers were provided by respondents: 
1. Good modelling practice would include a transparent, clear and explicit documentation 
of the model structure, equations and model assumptions. In addition, the model 
structure and parameter inputs need to be biologically plausible and the performance of 
the model to describe supporting data, in terms of fit to measured data, and an 
assessment of sensitivity and uncertainty in dose metric predictions that are relevant to 
toxicity and risk assessment should be evaluated.  
2. Clear description on the goal of the model. 
3. Description of assumptions and requirements of the model, determination of a 
realistic human exposure scenario (including time duration, frequency, level).  
4. Make/use a model that is as simple as possible for your question (minimal number of 
compartments) 
5. Model concept provided (scheme with blocks and arrows) 
6. Model representation by mathematical equations adequately describes the biological 
system, as well as the structure/properties of the chemical. 
7. Clear indication on the derivation of the model parameters, including the uncertainty 
around each of the parameters.  
8. Model implementation in any software language accurately reflects the mathematical 
equations. 
9. Model performance is evaluated using existing PK data or the model of a similar 
chemical has been evaluated with existing PK data. 
10. The final model needs to be transparent and replicable. 
11. Finally a global sensitivity analysis of model structure (Van Hoey et al., 2014), 
including their distribution in a probabilistic way, should be performed. 
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2.2 Survey discussion and follow up 
From this internal survey, several key findings were identified among the experts, which 
represented however only a small portion of the scientists and risk assessors involved in 
ADME/TK and PBK modelling and applications. Nevertheless, one of the findings is that 
the challenges in gaining regulatory acceptance of PBK models are a lack of 
understanding in model construction, interpretation of model results, and application of 
model results in a risk assessment context. This challenge is partly contributed by the 
lack of expertise in the use of these models among end users (such as regulators). 
Without the necessary expertise, it is difficult for end users to properly review or apply 
these complex models.  Another challenge is the lack of libraries and databases 
containing parameter values that have been thoroughly vetted to use by the PBK 
modelling community. Also, most PBK models are not coded in user friendly platforms, 
and thus, non-programmers may not be able to review model code. All of these 
challenges stressed the need for better communication between modellers and end 
users.  
Another important finding is that the 14 workshop participants prioritized ADME 
properties that should be addressed experimentally (Q9) in the following order: 
Metabolism > > absorption skin, GI and respiratory tract, renal excretion, transport 
mediated uptake/efflux, protein binding > intrinsic clearance > foetal disposition, 
placenta barrier. Also, the participants’ responses to the question of which experimental 
data are critical when constructing a PBK model (Q7) were similar to the list reported by 
Zhuang et al., 2016: MW, log P, pKa, basic, acidic, neutral, pH dependent solubility, PPB, 
blood:plasma ratio; apparent permeability (Caco 2 or MDCK), intrinsic clearance, protein 
concentration in in vitro test, in vitro test matrix binding, Vmax, Km, % enzyme 
contribution to metabolism, reversible inhibition, CYP inhibition / induction. 
The basis for Good Modelling Practice includes a clear and explicit documentation of the 
model structure, equations and model assumptions, according to the 14 workshop 
participants. In addition, the model structure and parameter inputs need to be 
physiologically plausible and the performance of the model needs to describe supporting 
data. Also, an assessment of sensitivity and uncertainty in dose metric predictions that 
are relevant to toxicity and risk assessment should be conducted. Model documentation 
should clearly state all the assumptions underpinning the model and justify the choices 
of model structure and values of parameters. Furthermore, model code should be 
carefully annotated.  
After the workshop, a new survey was compiled and released on the 11th of January 
2017 via the EU survey tool (EURL ECVAM_PBK_model_survey 2017) to understand the 
use and application of PBK models in broader scientific and regulatory communities. The 
results by country are available at http://bolegweb.geof.unizg.hr/questionaire/pbk/, 
(When accessing the link, double click on the selected country to retrieve results by 
country). The results from this international survey are summarized and analysed in 
Paini et al., (2017).  
 
 
 
 
 
 
 
  
20 
 
3 Identify regulatory needs  
3.1 Identify Regulatory Needs - summary of presentations  
 
Title: Evolving PBPK applications in regulatory risk assessment: current situations and 
future goals 
Dr. Cecilia Tan (EPA) opened the session with an introduction on applying PBK 
modelling approach to support regulatory risk assessment. As stated in the 2006 U.S. 
Environmental Protection Agency’s (EPA) Approaches for the application of 
physiologically based pharmacokinetic (PBPK) models and supporting data in risk 
assessment, “PBK model analysis is accepted as a scientifically sound approach to 
estimate the internal dose of a chemical at a target site and as a mean to evaluate and 
describe the uncertainty in risk assessment”. PBK modelling has the capability to predict 
internal dose metrics under new and inaccessible conditions, and thus, it has been used 
to support extrapolations from high to low doses, across species and life stages, to 
different exposure scenarios (e.g., route, frequency, and duration). PBK modelling can 
also quantify uncertainty and variability in physiology and pharmacokinetic properties, 
and examine their impacts on the overall uncertainty and variability on the predicted 
dose metric. PBK models that have been used to support regulatory decision making at 
the EPA are those that have been calibrated and evaluated with in vivo data (e.g., time 
course of blood or tissue concentration). The two main challenges, however, faced by 
the risk assessors are difficulties in identifying: (1) independent peer reviewers with 
knowledge in various disciplines (e.g., pharmacokinetic concepts, risk assessment 
application, mathematics, statistics, physiology, chemistry, biochemistry, computer 
programming) to properly review a PBK model; (2) a user-friendly platform for 
submitting PBK models to reviewers who are not programmers. As the paradigm shifts to 
developing PBK models using non-animal data, new challenges arise for regulatory 
agencies to evaluate the predictive capability and proper applications of these models. 
For example, the construction of these models can no longer include parameters that are 
required to empirically fit to in vivo data, and thus more thoughts are required on key 
parameters to be included in the model. Among the various model parameters, the most 
challenging one is likely to be the identification of metabolites that are likely to be 
generated in vivo. Case studies with chemicals that have existing in vivo data are 
valuable in examining some of these new in vitro and in silico approaches for estimating 
key parameters to appropriately capture the pharmacokinetic profiles. Also, existing PBK 
models in the literature can potentially provide insights on unique pharmacokinetic 
properties for chemicals with specific structure/properties (e.g., perfluorinated 
chemicals). 
Title: Global Tools Connecting Exposure, Toxicokinetics and Toxicity in Food Safety 
Global tools connecting exposure, toxicokinetics and toxicity in food safety: the 
contribution of the European Food Safety Authority(EFSA) was presented by Dr. Jean-
Lou Dorne (EFSA). Chemical risk assessment in the food safety area involves the 
classic steps bringing hazard and exposure together for risk characterisation. In the food 
safety area, sound hazard identification and hazard characterisation requires an 
understanding of both toxicokinetic (TK) and toxicodynamic (TD) processes for 
compounds entering the human body via the oral route. This enables the translation of 
external dose (exposure) into internal dose TK processes incorporating absorption, 
distribution, metabolism, excretion of chemicals (ADME) and toxicity for sound dose 
response modelling. Since its creation in 2002, EFSA has published over 2000 risk 
assessments for over 4000 substances in the human health, animal health and the 
ecological areas. Openfoodtox, EFSA’s open source database which provides summary 
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hazard data for individual chemicals, has been designed using the Organization for 
Economic Cooperation and Development (OECD) harmonised templates (publicly 
available as of December 2016). In addition, the development of open source TK tools 
and models to further integrate exposure, TK processes and toxicity in the human 
health, animal health and ecological areas are outlined. These include PBK models as 
well as dynamic energy budget models in ecotoxicology. Another challenge is the 
harmonisation of human and ecological risk assessment of combined exposure to 
multiple chemicals (“chemical mixtures”). The need to take into account international 
developments (e.g. OECD, WHO, the EPA, the three non-food committees of the 
European Commission) is highlighted as critical for the harmonisation of methodologies. 
Future developments of global risk assessment tools in the food safety area are 
discussed in the context of mechanistic alternatives to animal testing such as in silico 
and in vitro tools and tiered weight of evidence approaches tailored to support risk 
assessors in a practical way. International cooperation between national and 
international scientific advisory bodies and academic institutions concludes as the corner 
stone for the translation of 21st century toxicological research into harmonised 
methodologies and tools and for the training of the next generation of risk assessors. 
Title: What does the regulator need? 
Dr. Minne Heringa (RIVM) gave a perspective from an EU regulator, coming from the 
Netherlands National Institute for Public Health and the Environment (RIVM). Her 
presentation was prepared together with Dr. Peter Bos and Dr. Marco Zeilmaker. She 
showed how RIVM and other groups are working on the development of a new human 
risk assessment paradigm that enables an adequate prediction of human health risks 
based on alternatives to animal testing. The various published concepts all contain a 
tiered approach (e.g., Embry et al., 2014; Bos et al., 2015). Starting with very basic 
information in a first tier, more and better information is supposed to be collected to 
refine the risk assessment in every subsequent tier while identifying and focusing on 
target toxicity endpoints. This is somewhat similar to the Cooper Stage-Gate® model 
used by many industries for their innovation process of e.g. new chemicals. Starting with 
just an idea, more information on the market potential and safety is collected in each 
subsequent stage, with a go – no go decision at the gate following each stage (e.g. 
Edgett, 2015). These concepts show that in an animal-free risk assessment, performed 
within industries as required in the EU, PBK models will finally need to fit into different 
tiers, with increasing requirements to be met by the model in each subsequent tier. In 
addition, the pieces of information generated in each tier and the required input of the 
PBK model in the same tier need to match.  
The experience at RIVM with the use of PBK models for e.g. food safety issues is that 
most models in literature are too complex. They cannot be used for the questions faced, 
because too many input parameters are required, for which data are not available. PBK 
models should therefore be kept as simple as possible in accordance with the 
requirements of each tier. In conclusion, it was stressed that PBK models need to be 
kept as simple as possible with the preconditions that they are fit for the purpose of each 
tier and, in each tier, need to be compatible with the input data from e.g. in vitro tests. 
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3.2 Discussion of regulatory needs 
 
The experts were divided into three groups of 7 experts each, to address questions 
regarding identifying regulatory needs. Smaller breakout groups allowed better 
interaction and discussion, and tackled the issue by different point of views. This 
paragraph reports the points discussed by the members. Training for regulators (risk 
managers) and risk assessors was a first key point discussed; followed by model 
evaluation, guidance, and harmonized terminologies. Groups were then brought together 
to elaborate and share their discussion outcomes. 
 
With the current evolution of science and technologies, risk assessors and risk managers 
should keep up with development of NAMs. The modern methodologies highlighted from 
this breakout discussion on which regulators would need training include: -omics, TK & 
TD, organ on a chip, high-throughput screening methods, read across, Adverse Outcome 
Pathways (AOPs), IVIVE, and Integrated Assessment and Testing Strategies (IATA).  
It is not necessary for regulators to have detailed training on all diverse aspects of PBK 
models; rather, it may be sufficient to provide tailored training focusing on specific needs 
of each regulatory sector. For example, some risk assessors may need to run the model, 
so they will need to have the software and expertise to review and run model code. 
Other risk assessors may rely on a model peer review system to confirm the accuracy of 
model code. In this case, they may just need to be trained to interpret the data and put 
those into context. Risk assessors can also put together technical committees that 
consist of members with a range of expertise to review model code and interpret model 
results.  
In addition to the content of training, the format of training should also be tailored to 
achieve maximum effectiveness in understanding the use and application of these 
models. In addition to the traditional classroom setting, other formats could be used, 
such as webinars, ad hoc short courses, and more refined MSc course. Offering training 
online could potentially generate a bigger audience. For regulators who have more 
confidence in in vivo data, a way forward would be to make these courses more easily 
accessible.  
While training is essential, another critical need is to establish guidance and GMP on how 
to apply PBK models for the intended regulatory purposes. The GMP should include clear 
documentation to report model scope and purposes, details of model development and 
evaluation, interpretation of the results, and risk assessment applications. In addition, 
the individual responsible for a specific step in the process should be clearly identified, 
and thus, end users can easily identify individuals to request targeted training, if needed, 
on specific topic in the process. Listing individuals who are responsible for each step in 
the process also increases the transparency. The first thing that needs to be documented 
is the context in which the model is to be used, since a reliable model may be misused 
when results of the simulations are applied for the wrong purpose. For example, a first 
tier screening level model may not be appropriate for supporting the establishment of a 
regulatory guidance value. Currently, guidance for documenting PBK models is lacking 
from both modelling and regulatory communities on how to properly report and evaluate 
PBK models, or interpret and apply the model outputs.  
The Scientific Committee for Consumer Safety considers all available scientific data for 
the safety evaluation of cosmetic substances, including PBK modelling. In the most 
recent Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety 
Evaluation (SCCS/1564/15), they define the conditions for the use of PBK models 
submitted for risk assessment purposes. PBK modelling has already been accepted as a 
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tool for risk assessment or as supportive information in some of the chemical specific 
dossiers evaluated by the SCCS. These conditions can be a starting point for the new, 
general guidance document. 
While training and guidance are both essential, their maximum benefits cannot be 
achieved without frequent dialogue between regulators, modellers and proposers. The 
frequent dialogue not only allows the proposers to better understand the needs of the 
regulators, but also allows the regulators to provide feedback along the model 
development, evaluation, and application processes. For example, regulators already 
indicated at the workshop they prefer to use the simplest model possible (although some 
by necessity are complex models), as finding the input data is otherwise impossible. The 
dialogue can also help regulators identify their needs for specific training, and help 
proposers understand the criteria for regulatory acceptance. At the same time, there are 
also some challenges with the public’s perception of bias towards this process of 
reviewing being the primary concern. In this case, the model can be reviewed by 
independent peer reviewers or technical committees to minimize the concern.  Another 
challenge is that when a model is submitted to multiple regulatory groups, the frequent 
dialogue between proposers and regulators may become time-consuming. A potential 
solution to this problem is to set up a harmonised template for model evaluation, while 
still allowing the template to be flexible for the specific regulation and country. To set up 
such a template, we may also need a harmonized and defined "ontology". 
When a PBK model is developed for supporting regulatory risk assessment, the modeller 
may want to identify who will use the models (e.g., REACH, pesticides, food and feed) 
for which regulatory support. An overview of EU Legal framework and relevant regulation 
and directive can be found in Table 2. Identifying the end users early on can allow for 
better design of the study. For example, if a read across approach is likely to be applied 
by the end users, TK data for different chemicals may be important supporting materials 
that should be included in the submission package. In another example, the 
“throughput” (i.e. the number of models/chemicals) of the study can be determined 
when the modellers are aware of the specific regulatory endpoints. Once the end users 
are identified, the modellers will need to communicate with the users to understand the 
intended purpose of using PBK models. The required level of confidence in model 
outcomes would therefore be evaluated based on the relevance and goodness of in vitro 
data used for model development for the given purpose of model application. As the 
majority of toxicity and safety decisions are expected to be based on in vitro and cell-
based assay results, weight of evidence from human in vivo data may be used to 
evaluate model performance by regulators. In such cases, regulators may need to 
consider allowing data to be generated from human trials, e.g., micro-dosing, as 
appropriate. Finally, case studies are always a good way to convince regulators either by 
showing how absurd the old way is (using default Uncertainties Factors (UF)) with animal 
toxicity study data) or how the new way is more science-based. When developing case 
studies, the modellers should consider sufficient coverage of chemical space. 
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Figure 7. PBK/PBD models applied in risk assessment can strengthen the characterization and 
better define the dose- and species dependent influences on bioactivation, detoxification and 
possible adverse effects of chemicals thereby providing a basis for more reliable extrapolation from 
in vitro to in vivo or from animal experimental data to the human situation. 
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In a situation where safety assessment is conducted for a new chemical on the market 
and no ADME data are available, the following criteria may be used to facilitate 
regulatory acceptance:  
1. A model needs to be transparent, with usable code;  
2. Model uncertainty needs to consider biological plausibility, and be clearly described 
and quantified when possible;  
3. Uncertainty in exposure scenarios needs to be characterized, because this 
uncertainty will propagate to PBK model results; 
4. Consider user-friendly platform; 
5. A model needs to be fit for purpose and no more complex than that, and all 
required parameters should be measurable. 
 
 
In summary the key discussion points raised during the regulatory needs session were: 
• Published PBK models are often too complicated for risk assessment practice 
 Keep models as simple as possible. 
 Models need to be fit for purpose. 
 Most regulators are reluctant to deal with mathematical models/codes 
• Modellers will need to understand the regulatory need or purpose for which the model 
is to be applied and regulators will need to accept the shift to alternative methods. 
• Target the training – use case studies to show the use of models to incorporate TK 
into risk assessment. The more challenging training would be programming, which 
requires regulators to have certain technical skills 
• Establish criteria to educate and train reviewers for PBK models. 
• Dialogue between regulators and developers is also very important! 
• Facilitate communication on these tools 
• Clear documentation/reporting. 
• Different type of users will require different levels of information. 
• More efforts should be on analysis and evaluation of results and prediction rather than 
model evaluation. 
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3.3 Supporting information – Relevant Regulations & Directives 
 
The experts agreed that the following EU regulations were identified that could benefit 
from the application of PBK models (Table 2). 
 
Table 2. EU Legal framework and relevant regulation and directive. 
 Legal frameworks Regulation or Directive 
1 REACH Regulation (EC) 1907/2006 
2 Biocides Regulation (EC) 528/2012 
3 Plant protection products Regulation (EC) 1107/2009 
Regulation (EC) 283/2013 and Regulation 
(EC) 284/2013 
4 Novel foods Regulation (EC) 258/97, under revision 
5 Food improvement agents: 
a. Enzymes 
b. Additives 
c. Flavourings 
Regulation (EC) 1331/2008 
Regulation (EC) 1332/2008 
Regulation (EC) 1333/2008 
Regulation (EC) 1334/2008 
6 Food contact materials Regulation (EC) 1935/2004 
7 Feed additives Regulation (EC) 1831/2003 
Regulation (EC) 767/2009 
8 Veterinary medicinal products Directive 2001/82/EC, as amended by 
Directive 2004/28/EC and Directive 
2009/9/EC 
9 Cosmetics Regulation (EC) 1223/2009 
10 Detergents Regulation (EC) 648/2004 
11 Classification, labelling and packaging 
(CLP) of substances and mixtures 
Regulation (EC) 1272/2008 
12 Adequate risk management in scenarios 
of emergency response planning (ERP) 
and for the purpose of land use 
planning 
LUP; as required e.g., within the SEVESO 
II Directive 96/82/EC 
 
13 (Inter)national frameworks for OEL derivation, such as performed by national 
committees or the EC Scientific Committee on Occupational Exposure Limits . 
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3.4 Supporting information – Case studies 
 
Example of case studies capturing successful and ongoing efforts where PBK modelling is 
considered in a regulatory context.  
Perchlorate is both a naturally occurring and a man-made chemical that we are 
ubiquitously exposed to via food and drinking water. Perchlorate can inhibit the thyroidal 
uptake of iodide leading to thyroid hormone deficiencies. Thyroid hormones play a crucial 
role in the neurodevelopment of the foetus and infants. Pregnant women, their foetuses, 
and infants are particularly sensitive to thyroid perturbations with possible adverse 
neurodevelopmental effects due to perchlorate exposure. The most recent Federal 
Register Notice issued on June 6, 2016 reads “EPA has begun the process for developing 
a National-Primary-Drinking-Water Regulation for Perchlorate. EPA, with contributions 
from FDA scientists, developed a draft Biologically Based Dose-Response (BBDR) model 
to determine under what conditions of iodine nutrition and exposure to perchlorate 
across sensitive life stages low serum free and total thyroxine would result” (Federal 
Register Notice, 2016). One of the driving works for this collaborative PBK modelling 
approach with regulatory application was a PBK model developed in Lumen et al. (2013) 
that allowed for the prediction of perchlorate exposure scenarios accounting for the 
iodine nutritional status at which a late-gestation pregnant woman and her foetus are at 
risk for alterations in thyroid hormone levels to a level of concern. This model culminated 
from several model component developments over the years by experts in the field to 
study perchlorate kinetics and its dose-response. Lumen et al. (2013) model was 
developed using only available literature data and applying across species and life-stage 
extrapolation.  
MERLIN-Expo is a library of environmental multimedia fate models that was developed in 
the frame of the FP7 EU project 4FUN to provide an integrated assessment tool for state-
of-the-art exposure assessment for environment, biota and humans, allowing the 
detection of scientific uncertainties at each step of the exposure process. MERLIN-Expo is 
composed of fate models dedicated to non-biological receptor media (surface waters, 
soils, outdoor air), biological media of concern for humans (several cultivated crops, 
mammals, milk, fish), as well as wildlife biota (primary producers in rivers, 
invertebrates, fish) and humans by applying PBK modelling. These multimedia models 
together with PBK models can be linked together to create flexible scenarios relevant for 
both human and wildlife biota exposure. Standardized documentation for each model 
and training material were prepared to support an accurate use of the tool by end-users. 
Furthermore, one of the objectives of the 4FUN project was to increase the confidence in 
the applicability of the MERLIN-Expo tool through targeted demonstration activities 
based on complex realistic case studies. In particular, the 4FUN consortium researchers 
aimed at demonstrating the feasibility of building complex realistic exposure scenarios 
satisfying the needs of stakeholders, the accuracy of the modelling predictions through a 
comparison with actual measurements, and how uncertainty margins can improve risk 
governance. The case studies can be seen as reference cases that provide guidance to 
future users on how to apply the tool in different situations and how to interpret the 
results from the assessments with the tool taking into account relevant regulatory 
frameworks. 
Simcyp is one of the generic PBK modelling and simulation software for drug compounds. 
The availability of the generic PBK modelling tools like Simcyp is one the main reasons 
behind for the recent rise of PBK modelling in drug development (Jamei et al 2009, 
Bouzom et al., 2012). Simcyp provides a user-friendly platform to utilize the ADME data 
that are collected as part of drug development in a way to support both developers and 
regulators for several purposes, among which the most popular application has been the 
prediction of drug-drug interactions (Yoshida et al., 2017). In addition, applications for 
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predicting specific populations such as paediatrics have been increasing (Leong et al., 
2012). Advances in in vitro and in silico tools and technologies are behind the success of 
generic PBK tools like Simcyp in the pharmaceutical field. These models can reproduce 
the clinical observations and more importantly to simulate, i.e., predict, the untested 
clinical outcomes, allowing the evaluation of the effects of intrinsic (e.g., organ 
dysfunction, age, genetics etc.) and extrinsic (e.g., drug-drug interactions) factors, alone 
or in combinations, on drug exposure. There are several areas that are considered as 
current challenges in accepting model-informed drug development, which can provide 
insights into what the acceptance criteria should be for the PBK model-based drug 
development. Among those criteria, two of them are noteworthy including the adequacy 
of submitted PBK models is to be based on their intended purposes at different stages of 
drug development, i.e., determination whether a model is fit-for purpose and the need to 
identify and transparently communicate the knowledge gaps. Use of generic and user-
friendly PBK software like Simcyp has certainly been able to support meeting those 
challenges. 
At RIVM, generic PBK models were not used until recently, and custom-made models 
were applied for each case. These were kept as simple as possible. One example, with 
many illustrations of what a risk assessor encounters then, is the kinetic (not PBK) 
model used for the human risk assessment of orally consumed TiO2 nanoparticles 
(Heringa et al., 2016). The model was based on the findings of an in vivo rat study 
where organ and blood levels were determined at different time points after a repeated 
dose exposure had ended (Geraets et al., 2014). These data showed liver and spleen 
were the main organs where TiO2 was taken up, there was no elimination from the body, 
there was some elimination from the liver, but spleen levels only kept rising. A simple 
model with only a gut, a liver, a spleen, and a “rest” compartment was therefore built, 
with elimination only from the liver to spleen. The latter had no biological explanation, 
but was essential to let the model fit the data. Later, it became apparent from the 
hazard data that the testes and ovaries could be target organs, for which it was 
subsequently of interest to know the internal concentration. Therefore, an additional 
compartment was made for the gonads. However, fitting all parameters of the extended 
model to the data was problematic, as the values for the gonads differed by several 
orders of magnitude to those for the other organs. Therefore, the kinetic constants for 
the gonads were determined by fitting the extended model to the data, with the 
parameters for the other compartments fixed (determined in the earlier fit with the 
simpler model). This had no consequences for the rest of the model, as the transfer rate 
to ovaries or testes is negligible compared to those to liver, spleen and rest 
compartment. By applying this model to perform a risk assessment based on organ 
concentrations, a higher risk was found than when performing a risk assessment based 
on orally ingested doses (as is common). An explanation for this difference in this case 
may be the fact that TiO2 nanoparticles accumulate in the body, which makes 
extrapolation in time essential. A rat study cannot last longer than two years, while 
humans live much longer, and can thus accumulate much longer. For accumulating 
substances, kinetic models are thus essential to extrapolate to the longer exposure 
durations in humans. 
 
Within recent EFSA evaluations on food-relevant chemicals, PBK models have been used 
in two evaluations to assess species differences (Punt et al., 2017). Firstly, in case of 
bisphenol A, interspecies differences were assessed based on in vivo kinetic data from 
different species in combination with PBK modelling. Results revealed particularly 
differences between mice and humans, with mice having 14.7-fold lower plasma levels of 
bisphenol A compared with humans at a similar oral exposure, suggesting a higher 
sensitivity of humans. This difference was taken into account in setting the TDI (EFSA, 
2015a). Secondly, in the case of acrylamide, humans were found to have 1.4-2-fold 
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lower blood levels of the reactive metabolite glycidamide, suggesting relatively lower 
sensitivity of humans (EFSA, 2015b). Nonetheless, in the latter case the default safety 
margin of 10,000 for genotoxic carcinogens (covering a factor 4 for species differences in 
kinetics) was not reduced based on these data (EFSA, 2015b). 
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4 Constructing a PBK model without in vivo data 
 
4.1 Constructing a PBK model without in vivo data - summary of 
presentations  
 
Title: QIVIVE: PBK modelling-based reverse dosimetry of in vitro toxicity data 
The second session on construction of PBK models without in vivo data started with a 
PBK modelling-based translation of in vitro toxicity data to the in vivo situation by Dr. 
Jochem Louisse (WUR). The implementation of in vitro methods in toxicological risk 
assessment is slow. One possible reason is that in vitro methods provide concentration-
response data, whereas dose-response data are required to set a PoD to derive safe 
exposure levels for chemicals. PBK modelling provides a means to translate in vitro 
concentration-response data to in vivo dose-response data. These predicted dose-
response data may be used to derive a PoD that can be used in the risk assessment of 
chemicals. A few proof-of-principle studies are available that show that in vivo toxic dose 
levels can be predicted without using animals by translating in vitro concentration-
response data to the in vivo situation with help of PBK modelling. However, the approach 
needs to be optimized before it can be applied in toxicological risk assessment. For 
example, more insight in the uncertainties in the predicted toxicity dose levels is needed.  
 
Title: In vitro-based parameterization of PBK models 
Followed by a presentation on in vitro-based parameterization of PBK models by Dr. 
Miyoung Yoon (ScitoVation). The physiological, mechanistic basis of the PBK models 
is both their strength (in a sense that it provides the exceptional predictive power) and 
their weakness (as the development of PBK models can be expensive and time-
consuming). Obtaining chemical specific parameters, metabolism parameters in 
particular, has been the biggest challenge in expanding the use of PBK models to a wide 
range of chemicals as well as in gaining acceptance by regulatory agencies. Currently, it 
would be necessary to perform in vitro assays of the dose-response (capacity and 
affinity) for metabolic clearance. These assays are generally more expensive than the 
dynamic (toxicity) assays, since they necessarily involve the development of an 
analytical method for quantifying the concentration of the parent compound and its 
metabolite(s) in each tissue of interest over time. Quantification of the concentration of 
compound in the dynamic assays should also be performed or at least estimated as the 
in vitro kinetics is also critical in accurately determining in vitro dose-response 
relationship (Groothuis et al. 2015; Teeguarden and Barton 2004). Thanks to the 
advances of in vitro technologies that have occurred in the past few years for 
determining chemical metabolism and their variability in humans in vitro, the 
development of ‘generic’ or ‘ready-to-use’ PBK modelling platforms has been possible. 
These generic platforms will contribute to increasing the application of PBK modelling 
and eventually their acceptance by regulatory bodies by supporting risk-based decisions 
in different tier of safety assessment. The complexity of the PBK models would depend 
on the purpose (Wambaugh et al. 2015) of the intended use of the model along with the 
compound physico-chemical and biochemical characteristics and consequently deriving 
the types and complexities of in vitro assays for model development. The validity of the 
in vitro and in silico-based parameterization strategies has been shown with a number of 
environmental chemicals (reviewed in Yoon et al., 2012) and have been applied to build 
generic PBK modelling platforms for chemicals. In fact, there has been a rise in the 
development of generic PBK models for chemicals in recent years such as Population 
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Lifecourse Exposure-To-Health-Effects Modeling Suite (PLETHEM6) and httk package 
(Pearce et al., 2017). 
 
Title: High Throughput PBTK: Open-Source Data and Tools for Dosimetry and Exposure 
Reconstruction 
High Throughput PBTK: Open-Source Data and Tools for Dosimetry and Exposure 
Reconstruction by Dr. R. Woodrow Setzer. High throughput assays serve an 
increasingly important role in evaluating chemical safety. The ability to screen thousands 
of chemicals for bioactivity in hundreds of assays goes a long way towards addressing 
the problem of the very large number of chemicals in commerce with little or no 
toxicological information available. Concentrations of test chemicals in bioassays need to 
be converted to dose levels to be able to relate the bioactivity measure in the assays to 
potential effects in exposed people. With the inclusion of information about population 
variability and even crude exposure estimates, chemicals can be roughly classified or 
ordered in terms of potential concern. High-throughput toxicokinetics uses in vitro 
estimates of plasma protein binding and metabolic clearance to parameterize simple 
pharmacokinetic models, and adds in silico predictions of partition coefficients to 
parameterize more general physiologically-based toxicokinetic models. While the 
predictions of these models are usually less precise than those of chemical-specific 
models, we can characterize their uncertainty by comparing their predictions to in vivo 
data, and, to an extent predict when they will fail. We have improved prediction error by 
improving some of the computational details about partition coefficients. All of this is 
encapsulated in the R package httk, publicly available from CRAN. It includes relevant 
data for over 500 chemicals to run both one-compartment and general PBK models. The 
current version (1.5) incorporates demographic-specific information on population 
variability of the US population derived from the National Health and Nutrition 
Examination Survey (NHANES), and provides tools for using Monte Carlo methods to 
quantify variability of pharmacokinetic predictions.  
 
4.2 Discussion on challenges in constructing models 
The second breakout session was planned as the first one, smaller groups met to 
address challenges in constructing models with no in vivo data, rather, by applying 
NAMs, QSARs, and in vitro TK and TD data. The objective is to identify key elements that 
are required in PBK models that are designed to support regulatory risk assessment.  
 
When there are no data to inform model structure, a minimum PBK model should 
comprise of the following organs: liver, slowly and richly perfused tissues. Depending on 
the exposure route, a compartment representing the skin, intestine or lung should be 
added to the minimum model. If a compound is highly lipophilic, a fat compartment is 
required, and it may also be necessary for the model to describe the uptake into the 
lymphatic system. Finally, depending on the hazard data available more compartments, 
such as target organs, and biological processes can be added to the PBK model. After 
the model structure is decided, a decision tree could be useful to guide modellers to 
construct a PBK model without using in vivo data for calibration. Some suggested 
elements for such a decision tree are listed as following:  
 
                                           
6 http://www.scitovation.com/plethem.html 
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1. Start with the generic model structure and refine for specific chemicals based on 
chemical structure, physico-chemical properties, and biological similarities to other 
data-rich chemicals; 
2. Examine the mode of action (MoA) of a chemical analogue in vitro and/or in vivo to 
determine the in vitro studies that are most predictive of the fate in the organism for 
the chemical of interest. Applicability domain of chemicals should be well defined but 
quite difficult to do; 
3. Draw a realistic case scenario followed by sensitivity analysis. 
There is a high value in developing and using one compartment models parameterized 
with only protein binding and clearance data (Rotroff et al., 2010; Wetmore et al., 2012, 
2013, 2014; Tonnelier et al., 2012). The httk R package contains information for such 
models for over 400 chemicals (see chapter 4.3.2). While predictions from such models 
are inherently more uncertain than more chemical-specific models, they may still be fit-
for-purpose for risk-assessment related applications (Wambaugh et al. 2015). 
Steps for developing PBK models built solely using NAMs, in vitro, and in silico data are 
similar to those built based on in vivo data (adapted from figure 1): (i) problem 
formulation and identification of relevant exposure scenarios, including dose range and 
routes; (ii) construction of mathematical equations; (iii) search for existing models for 
chemical analogues to identify unique features that need to be considered; (iv) 
identification of values for model parameters from in vitro experiments or in silico 
methods carried out ad hoc, via the literature or in databases; (v) integration with other 
models if needed (in vitro fate and transport models); (vi) code implementation; (vii) 
model evaluation using local or global sensitivity analysis and model validation (check 
mass balance) by applying read across or comparison to similar models; (viii) analysis 
and interpretation.  
There is the need to build a framework describing how and when to use the different 
tiers of PBK models, staying within their applicability domain. As more information is 
gained and models develop there is an increase confidence in their utilization. The 
strategy would be to start with an aggregated model then move to more specific models, 
knowing where the decision points are for further testing. In using a more fundamental 
model, it is possible that a key pathway or MoA, specific to a given target chemical, will 
not be taken into consideration. In this respect the model may not be the most 
conservative in terms of risk assessment. One way to address this would be to build a 
chemically agnostic resource, for example a database of all known ADME/TK processes. 
The potential relevance of any of these processes for a given chemical can then be 
considered prior to determining which model would be the most appropriate to represent 
the system. As much information as possible concerning the MoA of the chemical should 
be gained. Important is to capture the knowledge to help in defining the equations that 
will describe our biological process/es captured by the PBK models. 
When using a PBK model to convert an in vitro point of departure (PoD) to external 
dose, it is important to evaluate which in vitro concentration should be taken as PoD 
(e.g., area under the curve or peak concentration), and how it corresponds to an in vivo 
situation. For example, the common practice assumes an in vitro PoD to be equivalent to 
a blood or plasma concentration, but is this assumption always valid (Rotroff, (2010), 
Tonnelier (2012), and Wetmore (2012, 2013, 2014, 2015)? The role of in vitro biokinetic 
study is crucial to translate a nominal concentration used in in vitro systems to the 
actual level of free concentration the cells experience and produce the effect. We can 
apply several methodologies to address this such as in vitro fate and transport models 
recently developed by several research teams (Kramer 2010a, 2010b; Armitage et al., 
2014; Zaldivar Comenges et al., 2017). A multimedia model approach can be used, 
however, the further you go in the tiers, the more certainty the exposure and effect dose 
estimates should obtain, to be able to rely on the margin of exposure. Additionally, is 
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worth mentioning the US FDA practice of ranking chemicals based upon Cmax/AC50 
which is described in Fallahi-Sichani et al. (2013). 
 
Values of some PBK model parameters can be directly measured (e.g., organ volumes, 
blood flows), but values of other parameters, such as clearance, are inferred from other 
studies. As pointed out by the results of the internal survey, metabolism is an important 
feature to be included in the model, especially when metabolites are the possible toxic 
moiety. The PBK model can be constructed based on different degrees of data 
availability, and metabolism could be included in the higher tier models. In addition to 
metabolism, transporters are another challenging piece to address. It is important that 
the data are produced according to the new OECD good in vitro method practice 
(GIVIMP)7. The GIVIMP document is meant to serve as a technical guidance on good 
scientific and quality practices to support the regulatory human safety assessment of 
chemicals using in vitro methods. Within the literature a vast number of in silico 
predictive models for ADME properties have been published, including models for skin 
and gastro-intestinal uptake, volume of distribution, tissue partitioning (particularly to 
brain), plasma protein binding, renal and hepatic clearance. Mostrag-Szlichtyng et al 
(2010) provide an extensive review of in silico tools (QSAR models and Software) for 
prediction of such properties which are relevant to PBK model building. Prediction of 
metabolism (rate, extent, nature of metabolites and potential for inhibition) are of 
particular importance and software used for predicting various aspects of metabolism 
has been reviewed by Kirchmair et al (2015). A common criticism of software for 
predicting metabolites is over-prediction i.e. theoretically possible metabolites are not 
differentiated from those that occur experimentally. In order to reduce over-prediction 
within the Meteor Nexus software (Lhasa Ltd, Leeds) Marchant et al (2017) describe a 
process whereby k-nearest neighbour analysis is combined with expert knowledge of 
biotransformation to reduce metabolite over-prediction). For example, if metabolism is 
very slow, it may not be detected in short term assay. Another example, Phase III efflux 
of metabolites cannot be picked up in silico. If the parent compound is metabolised, then 
a model including elimination pathways is needed. To do this, the first step is to 
determine which methods of elimination are relevant to the target chemical. For example 
if the chemical is known to be predominantly excreted unchanged in urine then 
investigation of metabolism is less relevant. Where a chemical is known to be 
metabolised or to undergo biliary excretion, predictive models representing these 
individual components of elimination may be required. In silico and in vitro models have 
been developed for predicting different processes involved in elimination. These include 
in silico models for total clearance (Lombardo et al 2014) and metabolism (Pirovano et al 
2015) and in vitro models for biliary excretion (Ghibellini et al (2006). However, more 
work is required in developing models for elimination and the applicability domain for 
existing models needs to be carefully considered before application to a range of 
chemicals. As more information becomes available and models are further refined they 
can be used with increasing confidence. One strategy would be to start with an 
aggregated model then move to more specific models, knowing where the decision 
points are for further testing. 
PBK models can be applied to relate the external exposure dose with internal 
concentrations that reached the organs can exert a dynamic effect at a cellular level. 
Integration of kinetics and dynamics information into a PBK/PBD model will help to 
determine better dose – concentration - time – response relationships (and dependence 
profile of cellular response) of the delivered dose. 
How can we trust a PBK model prediction if there are no in vivo data to evaluate the 
simulation (more in this topic can be found in chapter 5)? As a solution to this point, a 
                                           
7 http://www.oecd.org/env/ehs/testing/OECD_Draft_GIVIMP_in_Human_Safety_Assessment.pdf 
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read across approach could be used. For instance, referring back to those cases for 
which you do have data. i.e. use input parameters for “similar” known compounds for a 
PK read across. Re-parameterise existing model with inputs, which can be obtained, for 
the target chemical; maybe supplement any known in vivo data for surrogate 
compounds with in vitro studies for target. Use a model based on similarity, such as 
biological, behavioural similarity, and the influence of each parameter (e.g. log P, 
specific functional group known) should be checked by sensitivity analysis. Additionally, 
if the individual ADME properties could be predicted these data can be read across, since 
is not possible to read-across a Ct or an AUC curve. Or the read across approach could 
be done for similar chemical class for which PBK model already exists. Additionally to 
read across as a NAM another ascending technology is organ on a chip/human on a chip 
that can be applied to evaluate and gain trust in these new PBK models.  
The Threshold of Toxicological Concern (TTC) approach could be applied in predicting an 
internal concentration of concern / no concern (Cramer 1978; Munro 1996; Kroes eet al., 
2007). 
In terms of the most conservative estimation for risk assessment the worst case scenario 
should be assumed. For example in determining the potential concentration to which 
internal organs may be exposed absorption from the site of administration can be 
assumed to be 100% with metabolism being assumed to be 0%. In cases where the 
chemical is known to form a toxic metabolite the most conservative model would be one 
where metabolism is assumed to be 100% conversion to the metabolite of concern. In a 
similar manner, the extraction ratio (i.e. relative amount entering an organ of interest 
via the blood flow compared to the amount leaving) can be set to 0 or 1 depending on 
which is more appropriate to give the most conservative estimate for toxicity. For 
example, if the chemical is potentially toxic to the bladder, calculations assuming an 
extraction ratio of 1 for kidney may be more protective. 
Then the discussion shifted to the need for modelling platforms, such as MEGEN-RVis, 
PLETHEM, MERLIN-EXPO, which are open source and can be used by individuals with 
different degrees of knowledge about PBK modelling. These tools allow non-
programmers to run the model and learn about the behaviours of the model. However, 
the biggest concern of these open source modelling platforms is that funding sources for 
further development and maintenance are not stable. Most of these platforms were 
initiated by a research grant. But when the project terminates, the developers often 
cannot find other funding sources to continue the project. One suggestion offered by the 
experts to address this challenge is to develop specific features for end users for a 
charge. Such consortium may increase the confidence of the users on these platforms 
that have specific features designed for their needs.  
For model sustainability, it is essential to have access to model equations, as these can 
be easily coded later. There should be the possibility that when a model is changed the 
new model is updated and the changes recorded for end-users. The development of an 
open source library where all models developed could be placed, after a peer review 
process, was considered important.  
Discussion on extrapolation from in vitro to in vivo took place. QIVIVE is an essential 
process in linking an in vitro measured biological (adverse) readout to a potential in vivo 
outcome as it provides a means to consider exposure and dosimetry and enable the use 
of in vitro data for risk-based evaluations beyond hazard identifications. Multiscale 
modelling and models describing chemicals fate in vitro and in vivo contribute to the 
integrated decision-making process.  The challenges faced when applying (Q)IVIVE to 
risk assessment are, i) the fact that exposure in vitro has different elements than 
exposure in vivo; ii) the identification when metabolism plays a role in chemical mode of 
action, e.g., metabolic activation; iii) how to compare in vitro prediction to in vivo. To 
increase confidence in this end, we must be sure that the in vitro system is not lacking 
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metabolic competence when relevant, e.g., by ensuring the use of metabolically 
competent cell models to predict in vivo metabolic clearance. In the long run, prediction 
of human metabolism in silico needs to be achieved. In the short term, continued 
improvement of in vitro metabolism assays are recommended to reproduce metabolic 
rates and metabolite profiles comparable to in vivo. Concerning challenge iii), it is not 
always straightforward to relate an effect concentration or dose-response curve for an 
initial event, which may be eventually leading to the disturbance of cellular homeostasis 
in vitro, to a relevant in vivo exposure situation. Predicting the effect of in-life repeated 
exposure based on in vitro presents an additional challenge in using in vitro-based PBK 
models for risk assessment. Solutions to overcome these challenges are i) the evaluation 
and improvement of in vitro models to address these challenges; ii) identification of the 
assumptions and uncertainties in using  in vitro models for QIVIVE and IVIVE approaches 
themselves; iii) integration with other approaches such as AOP modelling to 
appropriately consider modes of action. The most important first step in this direction is 
to consider what the data requirements should be to ensure the relevance of the given in 
vitro models for the purpose in risk assessment, to develop appropriate PBK models.  
 
The main discussion points on the construction of a PBK model with no animal data are 
summarized below: 
 Use read across approaches for estimating TK properties. 
 Establish UF for IVIVE 
 Develop open access modelling platform to facilitate regulatory acceptance, although 
maintenance of such platforms may be challenging. 
 Highlight main fate/processes in organism [create a Knowledge Base of ADME / TK 
properties]. 
 Develop a decision tree (Wambaugh et al., 2015) to guide the construction of PBK 
models using only NAMs, in vitro and in silico methods.  
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4.3 Supporting information:  
4.3.1 ADME/TK Databases  
 
In 2008 ECVAM (former EURL ECVAM) commissioned from RIVM (the Netherlands) the 
development of a pilot database, ECVAM KinParDB (ECVAM Kinetic Parameters 
DataBase), with kinetic parameters of compounds used as reference substances in 
various in vitro toxicity tests. Briefly, the kinetic properties of chemicals can provide 
valuable information in human risk assessment. In vivo as well as in vitro, biological 
targets are exposed to concentrations of the compounds or their metabolites. 
Concentrations and their time course, mostly determined in blood or plasma, provide the 
most direct link between the observed or predicted in vivo effects and the effects 
observed in vitro. Accurate quantitative knowledge of the in vivo concentration-time 
relationship is therefore a prerequisite for the correct interpretation of in vitro toxicity 
test results.  
Classical compartmental modelling parameters were chosen to describe the in vivo 
kinetic properties as they fulfill the needs for prediction of in vivo concentration time 
profiles under linear conditions. Typical classical compartmental modeling parameters 
are systemic bioavailability (F), absorption rate constant (ka), volume of distribution 
(Vd) and elimination rate constant (ke). Protein binding parameters were added to 
facilitate calculation such as unbound substance concentrations. The database is filled 
with human and rat kinetic parameters (mainly based on intravenous and oral 
administration) for 100 substances following assessment of their reliability. Beside an 
input module (storage template) for the database, a retrieval template was developed to 
facilitate further use of kinetic data. Additionally a Kinetics Calculation Tool (ECVAM 
KinCalTool) was developed; this is a self-explaining calculation tool for the construction 
of a C,t-curve, using a 1- or 2-compartment kinetic model and the kinetic parameters as 
present in KinParDB. The KinParDB and the KinCalTool are currently publicly available, 
via the EURL ECVAM website (https://eurl-ecvam.jrc.ec.europa.eu/validation-regulatory-
acceptance/toxicokinetics) for use and we invite the scientific and toxicological 
community to make use of this application. 
Another publicly available resource is the online chemical database with modeling 
environment (oCHEM database) located at https://ochem.eu/home/show.do. This 
contains 500 ADME and toxicity relevant parameters for a range of chemicals; for some 
endpoints there are an extensive number of data points for others data are sparser. For 
example there are > 46, 300 log P values, however for specific tissue:plasma partition 
coefficients (e.g. heart, kidney, bone etc) there are fewer than ten chemicals. 
Parameters relevant to PBK model building include volume of distribution (1555 values), 
pKa (1589 values), Caco2 permeability (462 values), plasma protein binding 3857 
values) etc. Note that although the site is moderated and annotations may be made, it is 
possible for other users to upload information to the system therefore data quality 
checking is essential prior to using the data for model building. Similarity searching is 
also possible to identify similar compounds or those containing a given substructure.  
Przybylak et al (2017) reviewed 140 datasets of ADME parameters assessing their 
suitability for modelling purposes based on factors such as availability, size of dataset, 
format of data and nature of information provided. From this analysis, 31 “benchmark 
datasets” were identified for a range of ADME parameters such as extent of plasma 
protein binding, absorption, clearance, bioavailability etc. These datasets, predominantly 
based on data for drugs, have been made available in Excel format to assist other model 
developers. 
The BRENDA enzyme database (located at www.brenda-enzymes.org) is maintained and 
developed by the Institute of Biochemistry and Bioinformatics at the Technical University 
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of Braunschweig. Enzyme function data is extracted from the literature and quality 
checked by biology or chemistry graduates; it is available free of charge to academic 
users on-line and as an in-house database for commercial users. Data are available for 
83,000 enzymes from 137, 000 references including >135,000 KM values, >38,000 Ki 
values, >62,445 Kcat and 49,000 IC50 values. Data availability and values vary greatly 
for individual enzymes; however, this is potentially a useful resource from which to 
develop predictive models for enzyme activity. Pirovano et al (2015) demonstrated the 
possibility of using literature data to develop predictive models for Km and Vmax. 
Sources of data for PBK modelling identified either during the workshop or subsequently 
have been collated in table 3.  
 
 
Table 3. List of available databases available online that can provide valuable piece of information 
to build PBK models. 
Chemical Specific Parameters 
Name  Link 
US FDA drug database - 
drugs@fda 
https://www.fda.gov/drugs/informationondrugs/ucm135821.htm  
DIDB from U-
Washington (Seattle, 
WA, USA) 
https://www.druginteractioninfo.org/  
Drugbank https://www.drugbank.ca/  
Pharmapendium https://www.pharmapendium.com/#/login 
Merck Index https://www.rsc.org/merck-index 
GastroPlus 
ADMET predictor 
http://www.simulations-plus.com/software/gastroplus/ 
http://www.simulations-plus.com/software/admet-property-prediction-qsar/ 
Simcyp https://www.certara.com/software/pkpd-modeling-and-simulation/physiologically-
based-pharmacokinetic-modeling-and-simulation/ 
Simcyp free ADME 
calculator app 
https://play.google.com/store/apps/details?id=air.android.com.simcyp.calculators&h
l=it  
PopGen http://xnet.hsl.gov.uk/popgen/  
US EPA iCSS dashboard https://actor.epa.gov/dashboard/  
PubChem Compound https://pubchem.ncbi.nlm.nih.gov/search/ 
The Interspecies 
database – 
https://www.interspeciesinfo.com/  
 
ChemSpider http://www.chemspider.com/  
EDETOX database for 
dermal penetration data 
https://apps.ncl.ac.uk/edetox/ 
US EPAs ECOTOX 
database 
https://cfpub.epa.gov/ecotox/ 
ToxCast and Tox21 
datasets 
https://www.epa.gov/chemical-research/toxicity-forecaster-toxcasttm-data  
Httk https://cran.r-project.org/web/packages/httk/index.html 
on-line chemical 
modelling environment -
oCHEM 
https://ochem.eu/home/show.do 
KinParDB https://eurl-ecvam.jrc.ec.europa.eu/validation-regulatory-acceptance/toxicokinetics 
Brenda www.brenda-enzymes.org  
Przybylak DOI: 10.1080/17425255.2017.1316449 
OECD toolbox http://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm  
Episuite https://www.epa.gov/tsca-screening-tools/epi-suitetm-estimation-program-interface  
Physiological Parameters 
Name  Link/Reference 
Embedded in Simcyp  https://www.certara.com/software/pkpd-modeling-and-simulation/physiologically-
based-pharmacokinetic-modeling-and-simulation/ 
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Implemented in PkSim http://www.systems-biology.com/products/PK-Sim.html  
Built in Gastroplus 
ADMET predictor 
http://www.simulations-plus.com/software/gastroplus/ 
http://www.simulations-plus.com/software/admet-property-prediction-qsar/ 
UK Census https://www.ukcensusonline.com/  
Child growth graphs https://www.cdc.gov/growthcharts/cdc_charts.htm 
ICRP http://www.icrp.org/page.asp?id=145 
MEGen http://megen.useconnect.co.uk/  
US EPA Physiological 
Information Database 
PID database  
HERO Database 
https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=202847&CFID=90333472&
CFTOKEN=83385957 
 
https://hero.epa.gov/hero/index.cfm  
RIVM Interspecies 
database 
https://www.interspeciesinfo.com/  
P3M Price et al., (2003) Modeling interindividual variation in physiological factors used 
in PBPK models of humans. Crit Rev Toxicol 33(5):469-503. 
NHANES https://www.cdc.gov/nchs/nhanes/ 
Brown et al, 1997 Brown et al., 1997 (Toxicol. Indust. Health 13:407-484) 
PhysioBank https://www.physionet.org/physiobank/database/  
HESS http://www.nite.go.jp/en/chem/qsar/hess-e.html  
4.3.2 PBK modelling Software  
The recent discontinuation of a widely used modelling software product (acslX) has 
highlighted the need for software tool resilience. Maintenance of, and access to, 
corporate knowledge and legacy work conducted with discontinued commercial software 
is highly problematic. The availability of a robust, free to use, global community-
supported application should offer such resilience and help address the issue of 
confidence in mathematical modelling approaches required by the regulatory community. 
RVis, described below, is an attempt at providing such resource. A funding scheme to 
develop more of these open source softwares should be set up. Industries and academia 
are encouraged to collaborate and build these computational tools. Below, we 
categorized three types of computational tools: (i) programming software that has the 
capability to solve differential equations; (ii) open-source programs developed 
specifically for PBK modelling; and (iii) commercial PBK models platforms.  
 
1. Computer Languages/syntaxes – differential equation solvers  
Berkeley Madonna is arguably the fastest, most convenient, general purpose 
differential equation solver available today. It is relatively inexpensive and runs on both 
Windows and Mac OS. Developed on the Berkeley campus under the sponsorship of NSF 
and NIH, it is currently used by academic and commercial institutions for constructing 
mathematical models for research and teaching. (https://www.berkeleymadonna.com/)  
The MATLAB platform is optimized for solving engineering and scientific problems. The 
matrix-based MATLAB language is the world’s most natural way to express 
computational mathematics. Built-in graphics make it easy to visualize and gain insights 
from data. A vast library of prebuilt toolboxes lets you get started right away with 
algorithms essential to your domain. The desktop environment invites experimentation, 
exploration, and discovery. These MATLAB tools and capabilities are all rigorously tested 
and designed to work together. (https://nl.mathworks.com/products/matlab.html)  
R is a free software environment for statistical computing and graphics. It compiles and 
runs on a wide variety of UNIX platforms, Windows and MacOS. To download R, please 
choose your preferred CRAN mirror. (https://www.r-project.org/)  
acslX is a modelling, execution, and analysis environment for continuous dynamic 
systems and processes. 
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2. Computer programs developed especially for open source PBK modeling  
MEgen/RVis: MEGen is a model equation generator (EG) linked to a parameter 
database, RVis is a prototype application for the analysis of structure and performance of 
physiologically based pharmacokinetic (PBK), and other models, written in the free, open 
source syntax R; and are discussed further in Chapter 5.1. 
(http://megen.useconnect.co.uk/; Loizou and Hogg, 2011) 
Merlin Expo: MERLIN-Expo tool contains a set of models for simulating the fate of 
chemicals in the main environmental systems and in the human body (http://merlin-
expo.eu/; Ciffroy et al 2016). 
COSMOS KNIME Biokinetic workflows: The models developed within the COSMOS 
Project (SEURAT-1) have been implemented into flexible, freely available KNIME 
workflows, which can further be adapted to users’ needs 
(http://www.cosmostox.eu/what/webtutorials/). (Sala Benito et al., 2017) 
High-Throughput Toxicokinetics (httk) is an R package for PBK modelling, 
https://cran.r-project.org/web/packages/httk. One can use the package to calculate 
steady state blood levels; it contains a one-compartment and a 4-compartment model. 
For drugs, httk methods predict within order of magnitude of values measured in clinical 
trials (Wang, 2010). Measured protein binding, clearance, and calculated K’s from 
Schmitz models were applied and 100% bioavailability was assumed. AUCs predicted iv 
data, reasonably but for oral data, AUCs were over predicted, which might be due to the 
assumed 100% bioavailability. A limited correlation was found between the predicted Css 
and the human in vivo Css (R2 of 0.34) Important factors were found to be: Fup (fraction 
unbound), predicted Css (the higher, the worse the prediction), ionization (pKa_donor), 
and elimination rate. NHANES population variability in physiological parameters 
(comparable to POPGen) is part of the httk (Ring et al., 2017) Future planned 
refinements are: revised Ks, human gestational PBTK, and an inhalation exposure route. 
PopGen is a simulation program designed to clarify various population genetic events. It 
is meant mainly for teaching purposes. (http://cc.oulu.fi/~jaspi/popgen/popgen.htm)  
PLETHEM stands for Population Lifecourse Exposure-To-Health-Effects Model Suite. This 
computational platform is being developed by ScitoVation under a Memorandum of 
Understanding with EPA's National Exposure Research Laboratory and National Center 
for Computational Toxicology (Pense et al., 2017). PLETHEM will provide a freely 
available, open-source, user-friendly platform for rapid modelling across the source-to-
outcome continuum using only in silico and in vitro data. 
(http://www.scitovation.com/plethem.html)  
 
3. Commercial PBK models platforms  
The Simcyp’s Population-based Simulator, includes extensive demographic, physiologic 
and genomic databases which include algorithms which account for patient variability. 
This enables the user to predict drug behaviour in virtual patient populations instead of a 
virtual reference man, allowing individuals at extreme risk to be identified. 
(https://www.certara.com/software/pbpk-modeling-and-simulation/physiologically-
based-pharmacokinetic-modeling-and-simulation/)  
Gastroplus/ADMET/PBPK PLUS is a mechanistically based simulation software 
package that simulates intravenous, oral, oral cavity, ocular, inhalation, 
dermal/subcutaneous, and intramuscular absorption, pharmacokinetics, and 
pharmacodynamics in humans and animals. This smoothly integrated platform combines 
a user-friendly interface with powerful science to make faster and more informed project 
decisions! (http://www.simulations-plus.com/software/gastroplus/)  
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The Computational Systems Biology Software Suite (PKSim) contains different software 
tools and has been designed using a modular concept to allow efficient multi-scale 
modelling and simulation. The overall platform with its various software tools is 
implemented in a modular way as will be explained in more detail below. The central 
software tools are PK-Sim® and MoBi®. While PK-Sim® is based on a whole-body 
concept, the focus of its counterpart, MoBi®, is at the molecular level. However, both 
tools extend to additional physiological scales. (http://www.systems-
biology.com/products/pk-sim.html). Since 2017 the PKsim has become open-source 
under GPLv2 and is now available on github https://github.com/Open-Systems-
Pharmacology/Suite. 
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5 Assessing model credibility 
5.1 Assessing model credibility - summary of presentations  
Title: Challenges in assessing model credibility 
An introductory presentation to the session was given by Dr. Elisabeth Joossens 
(JRC). Model performance is a key factor when assessing its credibility. A common and 
good start to do this is by comparing model results against experimental data. If 
possible, for a whole set of reference data, or at least for some points. As a result, one 
gets an idea on how well the model managed to reproduce the set of experimental data 
but credibility can be increased by showing that these results are stable to any variation. 
So the comparison should be complemented by an analysis of the uncertainty and 
variability of the model. Variability refers to real differences over time, space, or 
members of a population and is a property of the system being modelled. It can arise 
from inherently stochastic processes, but also as a result of explainable and sometimes 
controllable differences among members of a population (inter-individual variability). 
While they are important to be reported, variability cannot be reduced. At the same 
time, every model has several uncertainties covering the lack of knowledge of the true 
system, the true value of a quantity or real relationships among quantities. They can be 
classified as scenario uncertainty, model uncertainty, and input (or data) or parameter 
uncertainty. When possible, they should be reported in a quantitative way but some can 
only be described in a qualitative way. These reducible uncertainties should be analysed 
via sensitivity. Sensitivity analysis shows how the uncertainty of the output of a model 
can be apportioned to the different sources of uncertainty in the model input.  
Title: Challenges of assessing model credibility in the light of uncertainty 
Dr. John Paul Gosling’s talk on the “Challenges of assessing model credibility in the 
light of uncertainty” started with a discussion of the separation of the verification and 
validation of a model. With the former being an exercise in checking implementation 
(does the model do what I think it is doing?) and the latter being the more important 
task of checking that the model is fit for purpose (is model an adequate representation 
of reality for our purposes?). A simple mathematical framework was proposed that could 
capture the uncertainties in using the model including both input uncertainties and the 
gap between model and reality. A brief discussion then followed of how various datasets 
from in vitro and historic in vivo sources could be used in such a framework. The 
conclusions from the talk were that predictive performance is not everything and that 
transparency and acceptance of the gap to reality are important in gaining acceptance of 
the modelling approach. 
Title: Uncertain credibility or credible uncertainty? 
The following talk was entitled “Uncertain credibility or credible uncertainty”, by Prof. 
Eann Patterson, (University of Liverpool). Model credibility was defined as 'the 
willingness of others to use model predictions to inform decisions' (Schruben, 1980) and 
hence is in gift of the decision-maker and not the modeller. A parallel was drawn to the 
nuclear industry where simulation reviews consist of three steps (Kaizer et al., 2015): 
determining the level of trustworthiness of the predictions from a simulation, identifying 
the level of trustworthiness required for the intended purpose and, using these two 
pieces of information, making a decision about whether to trust the specific simulation 
for the intended purpose. The role of model validation in providing evidence of 
trustworthiness was discussed and the accepted definition of model validation employed 
in engineering was highlighted (Asme, 2006), i.e. 'the process of determining the degree 
to which a model is an accurate representation of the real world from the perspective of 
the intended uses of the model'. Figure 8 was used to explain the relationship between 
the level of knowledge about the biology of a system, the extent to which measurements 
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of the system behaviour are approaches to validation were described, namely: 
quantitative validation based on codified procedures in engineering that can be used 
when measurement data is available; rational-empirical validation based on the 
principles of rationalism and empiricism that can be used when limited or sparse 
measurement data is available; and epistemic validation, based on simplicity, 
consistency and explanatory power, for use when there is little or no measurement data 
available. The presentation concluded with a short discussion of probabilistic approaches 
to handle approximate knowledge of non-linear dynamic systems and the potential 
support available from merging validation experience in digital twins.  
 
Figure 8. Schematic diagram illustrating the relationship between testable and untestable models 
that are based on known (i.e. principled) or unknown (i.e. unprincipled) biology together with 
approaches to performing a validation and the likely resultant level of credibility indicated by the 
greyscale [from Patterson & Whelan, 2017]. 
 
 
Title: RVis: A freely available application for the analysis of structure and performance 
of models written in R 
The session concluded with a presentation by Dr. George Loizou who gave a brief 
overview of the development of RVis, a prototype application for the analysis of structure 
and performance of PBK, and other models, written in the free, open source syntax R.  
The widespread adoption and application of PBK modelling in product development and 
safety assessment has been hampered by criticism that these models are data hungry, 
resource intensive, complex and require high levels of mathematical expertise and 
programming skills. Most criticisms can be addressed, as has been demonstrated, with 
the development of prototype, proof-of-principle, user-friendly web-based tools such as 
MEGen8 (Loizou and Hogg, 2011), for the rapid generation of PBK model code, and 
PopGen9 (McNally et al., 2014), a virtual human population generator. Both applications 
shift the emphasis away from the need for high levels of mathematical expertise and 
                                           
8 http://megen.useconnect.co.uk/ 
9 http://xnet.hsl.gov.uk/Popgen/ 
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programming skills to the understanding of the biology of toxicity and disease that 
should underpin chemical safety and risk assessment. Further development of such tools 
would continue to mitigate existing concerns and make this powerful approach more 
readily accessible to safety toxicologists and risk assessors.  
However, the greatest obstacle to the more widespread adoption of PBK modelling is 
most likely the availability of a common, transparent and independently auditable, free-
to-use platform for running models and analysing model structure and output. In 
response to this need the European Partnership for Alternative Approaches to Animal 
testing (EPAA) and the Health and Safety Executive (HSE) funded HSL (HSE’s Health and 
Safety Laboratory) to develop a user-friendly in vitro and in vivo exposure predictor. The 
motivation for this tool is the ultimate replacement of animal testing which requires the 
ability to predict equivalent human oral, dermal or inhalation exposures that are 
consistent with measured in vitro target tissue concentrations; an issue which can only 
be achieved using PBK modelling approaches. The output of this project was RVis, a 
prototype, proof-of-concept application for the analysis of structure and performance of 
PBK, and other models, written in the free, open source syntax, R. The first phase of the 
project was launched in June 2014 and finished in February 2016. In response to the 
data security concerns of EPAA partners, RVis was designed to be installed on a user’s 
Windows- based PC thereby obviating the need for the uploading of (proprietary) data to 
a web-based application. In June 2016 the European Centre for Ecotoxicology and 
Toxicology of Chemicals (ECETOC) convened a meeting of experts to garner feedback 
from evaluators of RVis from industry and regulatory scientists from the EU, USA and 
Japan representing the pharmaceuticals, chemicals, cosmetics and agrochemical sectors. 
Technical improvements needed in the next phase of RVis development were agreed and 
a second phase of development, funded by CEFIC-LRI began in January 2017.  
 
Figure 9. RVis: a general purpose modelling platform. Models in R syntax can be run, visualised 
and graphical output displayed. Model structure may be analysed using parameter elementary 
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effects screening and global sensitivity analysis (GSA) and parameter estimation using Markov 
Chain Monte Carlo simulation and Bayesian inference.  
RVis is, in fact, a general purpose modelling platform, not just an in vitro and in vivo 
exposure predictor (Figure 9). RVis features include the ability to load, run, visualise and 
plot graphical outputs from models. Model structure may be analysed using parameter 
elementary effects screening (Morris Test) and global sensitivity analysis (GSA) 
(extended Fourier Transform Sensitivity Test, eFAST) (McNally et al., 2011) and 
parameter estimation using Markov Chain Monte Carlo simulation and Bayesian inference 
(McNally et al., 2012). The parameter estimation feature is used to perform “reverse 
dosimetry” to reconstruct human dose or exposure concentrations consistent with 
measured biological monitoring data. An approach for the translation of in vitro 
concentration-response data to in vivo dose-responses will be implemented in the next 
version of RVis. 
Further development of RVis 
Two examples of improved features were demonstrated: The Lowry plotter and 
population generator modules (PopGen UI, user interface Figure 12). Figure 10 is typical 
of the graphical output from a global sensitivity analysis using the eFAST. In this 
example, model output is venous blood concentrations of m-xylene. The lines on the 
chart represent the time-dependent changes in the Total and Main effect sensitivity 
indices for each model parameter. The strength of this method is that it provides a 
quantitative analysis of model output variance. However, the interpretation of data in 
this format is difficult. Figure 11 is an example of a more intuitive presentation of the 
same data allowing easier interpretation. In this format each bar has two sections, the 
lower dark colour (purple) represents the “Main” effect and the upper lighter section 
(blue) the “Interactions” that parameter has with other model parameters. Together 
they represent the “Total” effect. The chart automatically ranks the proportional 
contribution each parameter makes to output variance from highest to lowest at any 
given time during the simulation. For example, in Figure 11 the Main effect of parameter 
“Fu” (fraction unbound) contributes about 26%, the “Interactions” about 16% giving a 
“Total” effect of around 42% of variance of model output. At any given time point the 
sum total of the Total effects of all parameters equals 100%.  
 
Figure 10. Extended Fourier Transform Sensitivity Test (eFAST) global sensitivity analysis output. 
The lines on the chart represent the time-dependent changes in the Total and Main effect 
sensitivity indices for each model parameter. 
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The width of the “ribbon” arising from the parameter with the highest total effect is a 
measure of the extent and contribution to variance of parameter interactions. The lower 
bound of the ribbon represents the cumulative total of the Main effects and the upper 
bound the cumulative total of the Total effects. In reality, due to multiple accounting of 
interactions associated with each parameter the total eventually exceeds 100%. 
However, we have imposed a strict limit for the upper bound of the ribbon such that it 
cannot exceed 100% minus the sum of the Main effects that are not included in the 
cumulative sum up to that point (top of the ribbon). The user can identify the number of 
parameters that account for any given proportion of Total variance, e.g., 100% by 
running a line from the y axis (Total =Main Effect + Interaction) to the ribbon then 
running a line down to the x-axis. Only those parameters to the left of that line have a 
significant contribution to Total variance. This information could be used to optimise 
probabilistic modelling such as Markov Chain Monte Carlo or conventional Monte Carlo 
sampling by ascribing distributions only to those parameters driving model output 
variability. This should significantly reduce computational cost. 
 
 
Figure 11. The Lowry Plotter: Intuitive interpretation of global sensitivity analysis. The upper 
panel shows a modified Pareto plot, known as a Lowry Plot, with parameters ranked from left to 
right according to the magnitude of Total effects at any given time during a simulation. The 
number of parameters that account for any given proportion of Total variance may be identified as 
shown with the broken line e.g., 100% by running a line from the y axis (Total (=Main Effect + 
Interaction) to the ribbon then running a line down to the x-axis. Only those parameters to the left 
of that line have a significant contribution to Total variance. The lower panel shows the time-
dependent model output for which the sensitivity analysis was conducted. Individual Lowry plots 
can be downloaded for any time point along the simulation by clicking on the line. 
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The selection of anatomical and physiological parameter distributions required for 
stochastic and population-based modelling will be made available by incorporating a 
population generator module into RVis. A prototype, stand-alone working version of this 
module known as, PopGen UI (PopGen User Interface) will be integrated into RVis. The 
user will generate virtual healthy human populations via PopGen UI which uses web-
services to access PopGen. Figure 12 is an example of the PopGen UI data page. A list 
recording the date, time and size of user generated virtual human cohorts appears under 
“My data”. A data file is selected by highlighting the file e.g., “18 Oct 10:17 n=10000”. A 
summary of user entries in the PopGen UI homepage such as dataset used, age, BMI 
and height ranges, ethnicity and parameter units etc., appears on the right hand side. 
The data can be downloaded as a csv or text file by clicking on the symbols just below 
the summary of inputs. The user can interrogate the cohort by plotting cohort 
parameters such as age and body mass against organ masses, blood flow rates and sex. 
In Figure 11 a plot of bone mass against age for male and females in a mixed cohort of 
black and Asian people from the UK Health Survey for England10 dataset is displayed. 
User defined percentiles for selected parameter distributions e.g., 5th and 95th will be 
imported into RVis parameter range fields for stochastic modelling. 
The further development of RVis would potentially address a number of other areas: 
1. Innovating chemical testing. RVis can help reduce chemical testing costs, time 
and animal use. Standard PBK models rapidly generated using MEGen and 
exported in R can be exercised and analysed using RVis. The incorporation of in 
vitro and in silico derived parameters provides the capability to assess potential 
bioavailability of new chemical entities in people and wildlife. Estimates of 
bioavailability can be used in tiered exposure assessment and integrated 
assessment and testing strategies (IATA) which help limit animal numbers and 
inform the design of specific animal bioassays to define critical dose-response 
information. 
2. Understanding everyday exposures to chemicals. PBK models can be used to 
predict consumer exposure of new and existing chemicals in commerce e.g., 
MERLIN-Expo a freely available software platform which integrates a library of 
environmental multimedia and PBK models (Suciu et al, 2016).  
3. Translating research outcomes for product safety. The biological basis of PBK 
model structure, the estimation of tissue dosimetry and the inclusion of 
biochemical mechanisms of toxicity provide the basis for data-informed, 
quantitative chemical safety and risk assessment. Scientifically supported 
uncertainty factors derived using quantitative, evidence-based models should 
increase consumer confidence in product safety. 
Possible Regulatory and Policy Impact 
The availability of a resource such as RVis could also have a potentially significant role in 
three other important areas: the development of internationally recognized good 
modelling practice (GMP) (Barton et al., 2009; Barton, et al., 2007; Loizou, et al., 2008), 
rigorous peer-review of PBK models and software resilience.  
Regarding GMP, RVis was designed to capture a sensible workflow where a model 
structure can be quickly and easily analysed using GSA. GSA is the most appropriate 
form of sensitivity analysis for models that describe non-linear processes such as 
saturable metabolism and receptor binding (Loizou, et al., 2008; McNally, et al., 2011). 
The open source, open access, free to use philosophy provides transparency and 
auditability of model code and performance have been proposed as important elements 
                                           
10 http://content.digital.nhs.uk/healthsurveyengland 
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of GMP. These attributes are also considered to be important features for fostering 
confidence in mathematical modelling techniques by the regulatory community. 
The features that foster GMP could also provide a viable and convenient platform for the 
peer-review of models. That is, models can easily be exchanged and independently 
evaluated to provide a more rigorous process for publishing in the peer-reviewed 
literature.  
 
 
Figure 12. PopGen UI. User generated virtual human cohorts appear under “My data”. A summary 
of user inputs are displayed on the right hand side. Data can be downloaded as a csv or text file by 
clicking on the symbols just below the summary of inputs. Cohort parameters such as age and 
body mass against organ masses and blood flow rates and sex can be displayed in graphical form. 
User defined percentiles for any parameter distribution e.g., 5th and 95th will be imported into RVis 
parameter range fields for stochastic modelling.  
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5.2  Discussion on model credibility  
 
The session on assessing model credibility took place on day two of the workshop and 
participants decided to have the discussion with the entire group rather than smaller 
group discussion.  
 
PBK models and other biological models need to be biologically plausible. Sometimes, 
modellers/mathematicians exclude some biologically important processes because these 
processes are not mathematically important and models should be kept as simple as 
possible. However, this must always be done in agreement with the toxicologists, to 
prevent omission of biologically essential steps. In this case, good documentation on 
model assumptions is critical for the modellers to demonstrate the credibility of their 
models to the reviewers and users. 
 
Visualization is a key feature when dealing with communication of these models. A 
graphical representation of the testability of a model versus knowledge of modelled 
system (figure 13) should aid in model acceptance and credibility. The graphs (figure 13 
A&B) are built on a previous published matrix (Figure 8, Patterson & Whelan, 2017). If a 
model falls in the bottom left region (testable and with full knowledge), confidence and 
credibility around the model is likely high. However, if a model falls in the top right 
region of the matrix (not testable with no knowledge of the system), confidence in the 
model is likely low due to the uncertainties associated with it. In other words, regulators 
are unlikely to make decisions with the models in the top right region of the matrix. In 
some sense, testable models do not really predict, but retrodict. Only when there are no 
test data, is a model used to make true predictions. In the case of untestable models 
based on known physics (e.g. Mars Rover), the models need to be simple but with 
explanatory power in order for them to be consider credible. 
 
The experts identified the need for establishing a framework to examine the credibility of 
computational models in biology. The framework should lay out the requirements for 
validating models with different degrees of knowledge and testability (e.g., quantitative 
validation, rational-empirical validation). In order to pinpoint where we are at the 
present moment on the matrix, a new matrix was drawn up (figure 13B). This could aid 
in quantifying the uncertainty we have now with animal models and can  help to 
convince the regulators that models built with in vitro, in silico and NAMs can be just as 
or maybe even more reliable and trustworthy. 
 
There was a short discussion about the complexity of biological systems. Biological 
systems are complex and dynamic, resulting in model solutions being patterns in state 
space rather than single-valued. Thus, similarly a measured value is representative of a 
particular, and perhaps unknown, starting state of system. Hence, to handle these 
issues, we need systems thinking and experience-based validation, perhaps involving the 
merging of all experiences to establish generic digital twins (see Patterson et al., 2016). 
It was suggested that there is a need to move to ‘credible uncertainty’ (instead of 
‘certain credibility’) for complex systems.  
 
There is disagreement amongst modellers as to the meaning of the terms, model 
evaluation, verification, and validation. Regardless of the appropriate term to use, the 
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purpose is to ensure that the model is predicting what it is designed to predict, and it is 
a reasonable representation of reality. After confirming that the model is a reasonable 
representation of reality for our purposes, several analyses may be used to “validate” a 
model, including sensitivity analysis, robustness analysis, assumption justification, model 
argumentation, structured calibration, predictive performance, proper scoring rules, and 
relation to reality. To “verify” a model, one needs to revisit model scope and check 
model equations and code. Finally, the following key elements were given to achieve 
model credibility by regulators: 
- Understand the model; 
- Understand the data underpinning the model; 
- State clearly the assumptions and hypothesis encoded; 
- Consider the gap between the model and reality, based on available 
observations.  
 
This gap consideration can be a description of what is lacking in the model. The 
outcomes of sensitivity analyses can be used to explain some of these deficits. But 
sensitivity analysis is a characterization of uncertainty in input mostly, so it’s dependent 
on input. In other words, sensitivity analysis cannot be performed on parameters that 
are missing in the model. One possible approach is to start with a more complex model 
and then remove parameters which it is not sensitive. The potential problem with this 
approach is that when there are many parameters with large uncertainties, they may be 
a flaw the uncertainty analysis. Another possible approach is to build both a simple 
version and a complex version of the model to examine their differences. A decision tree 
for model development could help to understand how complex should be the model for 
the purpose used (e.g. risk assessment). A high tier model would have smaller gap 
between simulation and reality, and at the same time, the utilization of sensitivity and 
uncertainty analysis could help to gain trust also with a high tier (highly complex) model. 
Additional observations were made by the experts about mixtures and co-exposure. 
What happens if not only one chemical is the dominant moiety for toxicity? How can 
interaction between chemicals be considered, such as synergism or inhibition, in the 
evaluation of the model predictions? The Matrix approach could be extended to address 
model evaluation for mixtures and co-exposure.  
An extensive discussion took place concerning terms validation / verification / evaluation 
/ assessment of fitness-for-purpose / checking validity / evaluating for a given purpose 
or for a specific application. Is it easier to describe the process by which we “check” 
models rather than deciding best words to use? EFSA opinion on uncertainty can be a 
useful resource (EFSA, in preparation) the document is currently in a draft phase, in the 
process of internal testing at EFSA of its applicability.  
In summary for the session on assessing model credibility, the following key points were 
highlighted: 
 
 Model credibility: biological systems are so complex, we need systems thinking and 
experience based validation.  
 Model Verification vs Validation, proposed a simple mathematical framework. 
 Define harmonized terminology. A first step would be to define and agree in 
terminologies such as robustness analysis, model argumentation, structured 
calibration and proper scoring rules.  
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5.3 Supporting information: The credibility matrix updated to our 
needs 
 
 
Figure 13A. Development of schematic diagram in figure 8 illustrating relationship between 
availability [or unavailability] of real-world data and epistemic strength [or weakness] of a model 
and its likely credibility indicated by grey level [darker is more credible] with possible approaches 
to validation highlight in yellow italics. The tracks show the possible development of a model from 
purely in silico data, through in vitro data, data from animal studies to clinical studies with 
increasing knowledge of biology and availability of real-world data leading to better probability of 
credible predictions. 
 
Recently, Patterson and Whelan (2017) have published a ‘credibility’ matrix (see figure 
8) in which the unavailability of real-world data to support model predictions is plotted 
as function of the epistemic weakness of the model. The likelihood of establishing 
credibility in the predictions from a model is represented as a greyscale in the ‘credibility’ 
matrix. Two developments of this matrix are shown in figure 13A and 14. Credibility is 
taken to mean the willingness of others, i.e. not the modeller, to make decisions based 
on the predictions from the model. It is expected that a model based on known biology 
whose predictions can be tested by comparison to real-world observations, i.e. in the 
bottom left corner in figures 13A and 14, will have a high credibility compared to one for 
which the biology is unknown and no real-world data is available which would be in the 
top right corner in the matrix. Data might be unavailable because of our inability to 
control and measure the real-world. Patterson and Whelan proposed strategies for 
validating or confirming computational models with different level of availability of real-
world data; and these are shown superimposed on Figures 13A and 13B, i.e. epistemic, 
rational-empirical and quantitative validation approaches. 
In figure 13A, the path of development of a computational model is shown based on 
discussions at the workshop. Starting in the top right corner, as an in silico model for 
which the biology is unknown and there is no real-world data. Such a model is largely 
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heuristic; but, its predictions can be used to design in vitro experiments that generate 
some real-world data, thus allowing the model to be translated downwards in the matrix. 
Further modelling, utilising the in vitro data, should allow the design of useful animal 
studies that both yield more real-world data and begin to confirm knowledge and 
understanding; thus, allowing the model to translate further downwards and leftwards. 
The same position might be achieved by ‘read across’ data, which by its nature implies 
initially less relevant data and knowledge. Finally, the predictions from the model, 
supported by data from animal studies, should enable the design of clinical studies. In 
turn, the clinical studies yield data that can be used to confirm the predictions, through a 
process of quantitative validation, which places the model in the bottom left corner with 
a high probability of stakeholders using its predictions in decision-making. This scenario 
might be described as the traditional approach to developing in silico models of biological 
processes and is illustrated by the locus in figure 13A. In this figure, the boxes 
describing likelihood of credibility have been removed to allow a fuzzy classification of 
the model. The same locus is shown using Greek lettering in figure 13B, i.e. a--d. In 
this figure, the boxes describing likelihood of gaining credibility have been retained, 
which means that the exact position of the model in each box depends on the case being 
considered, as does its allocation to a particular box when a model is shown on a 
boundary. Also, shown in figure 13B, is an alternative approach, a-b-c-d, which is not 
dependent on animal tests. The initial in silico model starts from the same position, i.e. 
the top right, and might consist of a simple model of an observed phenomenon described 
for instance in a QSAR. This leads to a more sophisticated, but still heuristic, model ‘b’ 
based on the understanding gained from model ‘a’. The predictions from models ‘a’ and 
‘b’ are used to design in vitro tests that enable the development of model ‘c’, which can 
be validated using the rational-empirical approach thus enhancing its credibility. Finally, 
this leads to the development of clinical studies and model ‘d’ supported by its 
predecessors and quantitatively validated or confirmed using clinical data; thus, placing 
it in the bottom left corner, i.e. a model whose predictions stakeholders, including 
regulators, practitioners, and patients, will use to make decisions. There are few 
examples of this alternative approach but it is proposed as the approach to which the 
modelling community should aspire. 
 
Figure 13B. Further development of matrix from figure 8 showing comparative loci for a 
traditional approach and for an alternative approach. The rationale for the locations of the model 
types, indicated by stars, are given in the side-bar.  
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6 Conclusions/Recommendations 
 
In order to facilitate acceptance and use of this new generation of PBK models, which do 
not rely on animal/human in vivo data in the regulatory domain, experts were invited by 
EURL ECVAM to (i) identify current challenges in the application of PBK modelling to 
support regulatory decision making; (ii) discuss challenges in constructing models with 
no in vivo kinetic and dynamic data and opportunities for estimating parameter values 
using in vitro and in silico methods; (iii) present the challenges in assessing model 
credibility relying on non-animal data and address strengths, uncertainties and 
limitations in such an approach; (iv) establish a good kinetic modelling practice workflow 
to serve as the foundation for guidance on the generation and use of in vitro and in silico 
data to construct PBK models designed to support regulatory decision making. The use 
of a matrix to underline and quantify the uncertainty associated with the new 
generation of PBK models compared to the models developed using animal models would 
be desirable. 
 
The experts noted that there is a lack of transparent, accessible and easy-to-use 
software and/or platforms that could easily build and solve PBK models. Such tools 
would improve the likelihood of adoption of these models within the regulatory 
community11. Development and refinement of existing web applications and PBK model 
platforms to be able to perform IVIVE and reverse dosimetry in an automated way is 
needed; with the flexibility to be interoperable with AEPs and AOPs. In addition, there 
should be an increase in communication and training of the regulatory community, 
such as risk assessors and risk managers. As reported in the EURL ECVAM TK strategy 
there should be more data available (in libraries and in databases)to build both QSAR 
and PBK models and the in vitro methods to produce these data should be standardised. 
In vitro methods for which we would need more standardisation are (from high to low 
priority): 
1. Liver metabolism (clearance and/or Vmax and Km) 
2. Absorption in lung and intestine (for skin absorption there already available an 
OECD test guideline) 
3. Protein binding 
4. Renal excretion 
5. Transporters 
A recommendation from the experts was to develop/refine/adapt good modelling 
practice, as well as to generate harmonized terminology/ontologies. This working 
group proposed the drafting of a guidance document for good modelling practice for 
PBK12, which could be extended to other in silico biokinetic models. With the increasing 
demands for alternative methods within the risk assessment framework, the need to 
develop PBK models has also increased. Existing guidance documents of WHO (2010) 
and EPA (2006) and the less PBK model-specific documents of EFSA (2014) and CEN 
(2015) require updating with respect to the current trends, since science and risk 
assessment are continuously evolving. The challenge is the use of in vitro data or in 
silico predictions to build these models and integrate and use of them within IATA or 
AEP/AOP concepts. EFSA and ECHA are currently working on developing guidance on the 
use of toxicokinetics and metabolism data and bioaccumulation in chemical risk 
assessment. As an example Schultz et al., (2015) propose a strategy for structuring and 
reporting read across predictions of toxicity; supplementary information includes a 
                                           
11 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258408/ 
12 PBK, PBBP, PBPK, PBTK… are representing the same type of models, Physiologically Based Kinetic models. 
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document for reporting the information which includes fields for toxicokinetics and 
metabolism – for assessing similarities between target and source chemicals. 
The experts elaborated on the importance of being transparent about the model 
construct and applications to support assessment including model credibility. The 
experts offered several recommendations to address commonly perceived limitations of 
parameterizing PBK models using non-animal data, such as the application of the free 
concentrations. One of the key recommendations identified was the need for a guidance 
document on building, reporting and documenting PBK models using non-animal data, 
for interpreting the model analysis for various risk assessment purposes particularly in 
the regulatory context (e.g., incorporation of PBK models in integrated strategy 
approaches, integration with in vitro toxicity testing and adverse outcome pathways 
[AOPs]). The uncertainty and variability in PBK modelling, and fledgling GMP (Loizou et 
al., 2008) proposed and reported should be further developed and should include 
guidance for PBK models built using QSARs, in silico data and NAM. The use of a matrix 
in a new risk assessment paradigm, to underline and quantify the uncertainty associated 
with the new generation of PBK models, compared to the models developed using animal 
models, would be desirable. With the information gain during the workshop we adapted 
the workflow reported in figure 1, now depict in figure 14. 
Finally the experts of the workshop recommend the establishment of an international 
working group for PBK models in addition to an international working group on the 
selection and standardization of in vitro methods for kinetic parameters necessary for 
PBK modelling. The first working group should establish criteria for model construction 
and model evaluation. A group of peer reviewing scientists should be available to put 
into place the peer reviewing system. US EPA already uses independent scientist to peer 
review their models. There should be criteria to select the people that will review the 
models, and provide them with templates and check lists to assist them in this process.  
In Table 4 we provide a summary of recommendations, status and solutions/actions 
taken from the latest workshop held at EURL ECVAM in 2011 and from the 2016 
workshop. This was done to make a clear overview of where efforts across the 
international community are put on and will be with respect to PBK model development 
and implementation.    
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Figure 14. Proposed workflow after discussion and following the recommendation from the 
workshop.
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Table 4 Summary of recommendations, status and solutions/actions from the latest workshop held at EURL ECVAM in 2011 and from the 2016 workshop.  
Recommendation 
(Bessems, 2014) 
EPAA – EURL ECVAM 
Workshop 2011. 
Status Recommendation EURL 
ECVAM 2016  
Possible solutions/Actions taken 
  Training & 
Communication  
CEC at conference (applied for EUROTOX 2018 
and SOT 2018); Scitovation PBK model course 
(November 2017); 
PBK course for master students, online course 
through Kansas State University Global Campus 
(early 2018). Additionally webinars and ad hoc 
meetings such as the CAAT academy 
webinar/course (September 2017). 
Set up databases for 
kinetic data 
Ongoing efforts by scientific 
community (interspecies DB 
https://www.interspeciesinfo.c
om/), see table 3. 
Databases of input 
parameters from in 
vitro and in silico data  
Ongoing activities 
ECVAM KinPar database  
HESI group on databases (Bier, contact person 
Dr. M. Embry) 
EFSA TK plate 
EURL ECVAM databases of in vitro and in vivo 
biotransformation rates in fish and mammalian 
species. 
  Funding scheme to 
develop software 
To be discussed 
Develop free to use, 
readily accessible 
PBK model web 
applications. 
The scientific community is 
engaged and examples are, 
among others, Megen/Rvis; 
COSMOS KNIME biokinetic 
models; PLETHEM. 
Open source of libraries 
of PBK models (already 
reviewed)  
Make available reviewed code into one place 
accessible to all.  
Such a repository is an aim in the proposed 
COST Action Kinetics 2.0. 
  Guidance for GMP for 
new generation of PBK 
models 
Proposal sent at OECD and endorsed by WPHA, 
EAGMST (interested WNT and QSAR toolbox 
working group) 
  Decision Tree for new 
generation model construct 
To be refined and elaborated and included in 
OECD PBK guidance 
  The matrix approach to 
gain credibility 
Develop case studies – to be done 
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Permanent 
international group 
of PBK model 
reviewing experts 
Was not done until now and 
was also highlighted by the 
2016 PBK model workshop.  
TASK FORCE for model 
peer review 
HESI PBK  working group (March 2017) contact 
person Dr. M. Embry;  
Results from ECVAM international survey to 
establish list of experts (March 2017). 
COST Action proposed, which includes work 
package on PBK models. The group of reviewing 
experts can be identified in there. 
  Scoring system for model 
peer reviewing and 
creation of a template. 
HESI PBK working group (March 2017) contact 
person Dr. M. Embry. 
Can also be included in the COST Action Kinetics 
2.0 (RIVM). 
Develop in vitro tools 
for high throughput 
measurements of 
portioning and 
expand the 
applicability domains 
of various tools such 
as absorption 
methods 
 Standardization of in 
vitro methods for: 
1. Liver metabolism  
2. Absorption in lung and 
intestine  
3. Protein binding 
4. Renal excretion 
5. Transporters 
Workshop in Leiden, NL, on in vitro methods for 
toxicokinetics in October 2017 
Included in COST Action Kinetics 2.0. 
Develop high 
throughput and low 
cost analytical 
facilities to measure 
chemicals in 
physiological media.  
To be done  Not discussed 
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7 Next steps/actions 
 
An action of the PBK workshop was a proposal submitted to the EGMAST group 
within the OECD, in early December, to seek their support to develop further this 
guidance document (see ANNEX). There was emphasis and need of a guidance to 
incorporate PK concepts, physiology, in vitro, in silico approaches, NAMs, with 
programming, mathematics and statistics; to develop guidance on alternatives. 
A decision tree needs to be refined and elaborated on, for PBPK model 
development (similar to figure 1 and described in chapter 4.3) without in vivo 
data, based on physicochemical data, in vitro data, NAMs and in silico methods. 
For instance, taking into account PBK predicted internal dose metrics vs. in vitro 
points of departure from toxicity testing (and how in vitro results link to in vivo 
adverse outcomes) for a tiered assessment. 
A public repository is needed for already developed and peer reviewed PBK 
models. This will be important, as once there is a repository for PBK models (for 
example, considering the AOP wiki format), relevant documentation can be 
introduced and can include a quality certificate following evaluation from an 
independent peer review. This is line with the work reported in Lu et al., (2016). 
Such a repository will allow for the curation of more case studies and in the 
creation of libraries of ad hoc PBK models that could be used for training 
purposes, for performing risk assessment, for conducting in vitro to in vivo 
extrapolation, and importantly to inform decision makers efficiently in the current 
state of science for the use of animal free models in regulatory applications.  
Establish a Task force for model software – 
1. A Linkedin group on PBK model developer could be created 
2. HESI PBK model working groups.  
These communities should try to establish: How they peer review model codes. 
Which universal language to use; will it be possible to write model codes using 
one common universal language?  
Build a core expert group for training for new modellers and risk assessors 
taking the example of the AOP training provided by JRC to EFSA, a similar 
training with focus on PBK model development, evaluation and application should 
be set in to place. This can be done with direct specific courses or as a continuous 
education course during conferences, like EUROTOX (2018) and SOT (2018). 
More communication with regulators: no in vivo data for model evaluation 
when in vivo data are not allowed to be collected (take responsibility!) – Use 
social media (like Linked-In) to establish a direct dialogue between PBK work 
groups and regulators (both risk assessors and risk managers) to improve 
communication and understanding of these models.  
There is a need to create a community to address ADME/TK and PBK models 
issues. With the needs for several international working groups to further work on 
these tools, this requires cross-talk to ensure compatibility of the in vitro methods 
with PBK models in addition to cross-talk with regulators to fit the total risk-
assessment framework. A COST Action proposal has now been submitted to form 
the international network to ensure this cross-talk. In addition, such a COST 
Network would provide the recommended training, repository of PBK models and 
standardization of in vitro methods and QSARs. However, funding resources for 
research and development would still be necessary.  
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Terminology definition 
Validation: In the CEN WS document “Standard documentation of large chemical 
exposure models” the term “Validation” is used in the context of Model 
Evaluation. The document attests: Model evaluation is seen here as the 
assessment of how accurately mathematical models represent the real world, 
e.g. the complexity of environmental and/or human systems. Typically the 
evaluation of complex exposure models is difficult to conduct because 
empirical data are seldom consistent regarding space and time and because 
key input data are often lacking. Model evaluation is frequently based on 
comparisons between the output from deterministic simulations and that 
from single experiments. However, it is now widely recognized that the 
impact of uncertainty and variability should be integrated in model 
validation”. However, there is not a specific definition for the term “Validation 
“.  
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Annexes 
Annex 1. Pre conference Material 
Proposed questions/statements for discussion  
What do we need to provide in order to have PBK models accepted by regulators, 
in order to reach a whole new level in regulatory decision making?  
Regulatory Acceptance: Challenges in using PBK model to support 
regulatory decision making 
 Do we need guidance? if not what do we need 
 Integration in/with IATA/AEP/AOP: Where is applied and how can PBK model 
play a role in IATA and AEP/AOP framework. 
Challenges in assessing model credibility 
 Model complexity versus simplification (how confident can you be?) 
 Validate/Verify the model code (mass balance) and the model predictions; 
Identify challenges in evaluating model performance when no in vivo kinetic 
data are available for comparison. When model simulations cannot be 
evaluated/validated using in vivo data, how do we increase confidence in the in 
vitro and in silico tools used to parameterize a PBK model?  
 Sensitivity analysis Global versus Local 
 Uncertainties 
Challenges in constructing models with no in vivo kinetic & dynamic data 
 Try to relay only on the use of in vitro data and in silico prediction when 
building your PBK model Quality and quantity of input parameters (which are 
mandatory and which are optional?)  
 Develop the conceptual model, identify key model components required to 
properly describe a chemical’s ADME behaviours to achieve the intended 
purpose; Identify challenges in developing a conceptual model when in vivo 
kinetic data (e.g., time course of blood/tissue concentrations) are not available 
to inform a chemical’s ADME behaviours.  
 Translate the mathematical equations into computational codes; Identify 
challenges in peer review process when reviewers may not have the 
programming software used to code the PBK model, or may not have the 
programming skills to review a PBK model coded in unfamiliar programming 
language.  
 Define and obtain the model parameters using high-quality in vitro 
measurements or in silico predictions; Identify challenges in applying in vitro 
and in silico methods to generate values of ADME parameters, or locating 
existing resources (e.g., databases, publications) that contain required data. 
 Use of in vitro effect (TD) data to link effect to dose: QIVIVE 
 Translate the in vitro concentration to actual in vivo human relevant dose. i) 
Physiology IVIVE, scale up; Pharmacology/pharmacokinetic IVIVE, simulation 
of effect in vitro concentration to external; Kinetic & dynamic IVIVE, linking in 
vitro data of effect to external dose [QIVIVE, comparison, forcing etc].  
Regulatory Acceptance: Solutions 
 What to do next? How to apply/implement good modelling practice? Approach 
OECD/CEN? To develop a guidance document? 
 Propose Training to Regulators and Scientists of these tools. 
 Propose to develop a Tool box (similar to the QSAR toolbox) to integrate in a 
common place a library of PBK models (Lu et a., 2016) for application in Risk 
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assessment; provide links to software's that can be used to build PBK models, 
and to integrate in the software generic and specific uncertainty and SA.  
 Define case studies? 
Additional discussion bullets provided by workshop experts: 
Dr. Woody Setzer (EPA, USA) 
 Any model used in risk assessment (or for any other purpose) needs to be 
accompanied with an honest quantitative assessment of its likely precision 
(e.g., measured concentrations are likely to be within an order of magnitude of 
predicted concentrations half the time). Note that this includes not just 
uncertainty in parameter estimates, but uncertainty about model structure and 
issues involved in extrapolation (e.g., how likely is it that there are unmodeled 
processes that result in a two-fold change in predicted concentrations?) 
 What tools do we have to give credibility to such statements, and how 
acceptable would they be to risk assessors? 
 One way to think about tiering or risk assessments is that as we go from, say 
screening and prioritization, to individual risk assessments for critical 
chemicals with potentially high exposures, we need increasingly precise model 
predictions. How do we calibrate this (e.g., we need to be within 100-fold for 
screening, but within 2-fold for a high-visibility assessment). 
 All this applies to assessment of variability, too. 
Dr. Cecilia Tan (EPA, USA) 
 Do the regulatory agencies, including internal experts, decision makers, and 
external reviewers, have the expertise necessary to evaluate a PBK model 
(including structure, parameters, predictive capability), as well as the 
appropriate use in risk assessment? If not, how do we help build that 
expertise? 
 How many tiers do we really have for PBK applications? In reality, is it possible 
that regulatory agencies will accept either (1) screening/prioritization for 
models that have no in vivo data to calibrate/evaluate; and (2) replacing 
default uncertainty factors with model predictions for models that have in vivo 
data to calibrate/evaluate? 
 Acknowledging the importance of identify metabolites (and its hazard), what is 
the level of uncertainty allowed for PBK predictions when the level of 
uncertainty in exposure predictions may outweigh any uncertainty in PBK 
predictions?  
 While a generic PBK model that includes intrinsic clearance rates and protein 
binding may be sufficient for many chemicals, how do we identify those 
chemicals that have some unique PK properties (e.g., perfluroonated 
chemicals)? 
Dr. George Loizou (HSL, UK) 
 Can an open access free-to-use modelling platform increase uptake and 
acceptance of PBK modelling in general and for regulatory applications in 
particular? 
 Can such a platform help improve the model peer-review process? 
 How can such a resource be maintained? 
 
Dr. John Paul Gosling (UNI Leeds, UK) 
 What matters more: having a model that effectively captures reality or having 
a model that is adequate for our purposes? 
 How much do we trust existing in vivo data that is used to parameterise PBK 
models? 
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Dr. Minne Heringa (RIVM, NL) 
 What questions are there, for which we need PBK models?  
 What features should a PBK model have to answer a certain one of these 
questions? What criteria should it meet then?  
 What parameters do we then need to determine with e.g. in vitro assays 
and this possible yet?  
 How do we ensure the PBK models are user-friendly?  
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Annex 2. OECD proposal for a guidance on PBK modelling 
Sent to EGMAST / WPHA – OECD - in December 2016 
A proposal for the development of an OECD Guidance Document for 
characterising, validating and reporting Physiologically Based Kinetic 
(PBK) models intended for regulatory application that are based on data 
derived from non-animal methods 
Physiologically Based Kinetic (PBK)13 modelling is a scientifically-sound approach 
to predict internal dose metrics for chemical risk assessment applications. 
Traditionally, the calibration of internal model parameters and the validation of 
the performance of the PBK model rely heavily on relevant in vivo data. However, 
due to the advancement of scientific knowledge concerning Absorption, 
Distribution, Metabolism and Excretion (ADME) processes within target species, 
the improvement in ADME/TK specific in vitro and in silico tools and the 
widespread availability of sophisticated modelling platforms, there is a strong 
shift towards the development of PBK models which rely primarily on non-animal 
data for their construction. Another important aspect to consider in relation to 
this new generation of PBK models is that there are typically very little in vivo 
reference data for the chemicals and species of interest to provide a basis for 
traditional quantitative model validation (i.e. statistical comparison of model 
predictions with equivalent in vivo measurements for a set of reference/target 
chemicals). 
The ultimate aim of the Guidance will be to establish the credibility of this class of 
PBK models in order to promote their acceptance and use in a regulatory context. 
The intention is to provide practical guidance to model developers and end-users 
on i) how to properly characterise their PBK model (e.g. model elements and 
construction, underlying principles and assumptions, internal parameters and 
their estimation, model implementation/coding etc.), ii) how to validate the 
model to assess its performance (e.g. model verification, sensitivity analysis, 
uncertainty assessment, applicability domain, limitations, etc.) and iii) how to 
comprehensively report and describe the model in terms and a format that an 
end-user (e.g. risk assessor) of the data could readily understand and trust.  
There are several existing guidance documents on developing and reporting 
traditional PBK models that are calibrated and evaluated using in vivo data e.g. 
WHO (2010)14, EPA (2007)15, CEN CWA 16938 (2015)16. The European Medicines 
Agency (EMA) is currently (2016-2017) working on a guidance document for 
qualification and reporting of PBK models which are focused primarily on the 
assessment of drug-drug interactions and understanding TK in children, as well as 
qualification of PBK modelling platforms commonly used to support TK aspects of 
the regulatory submission of new drugs17. Although aspects of these guidance 
documents are relatively universal and should be taken into account, they are all 
based on the premise that model performance must be ultimately assessed by 
direct comparison on predicted TK profiles with equivalent in vivo data. 
In a recent international PBK model workshop held at the JRC in November 2016, 
experts recommended that such a Guidance Document be developed at 
international level.  
13 PBK is synonymous with PBPK, PBBK, PBTK.  
14 http://www.who.int/ipcs/methods/harmonization/areas/pbpk/en/ 
15
https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=157668&CFID=72277452&CFTOKEN=721
62106 
16 https://www.cen.eu/work/areas/chemical/Pages/WS-MerlinExpo.aspx  
17http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/clinical_pharmacology_pharmacok
inetics/general_content_001729.jsp&mid=WC0b01ac0580032ec5 
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